Rezeptorinteraktion von Agonisten, Antagonisten und partiellen Agonisten

  • Enno Freye


Opioide können generell in reine Agonisten, Antagonisten, gemischtwirkende Agonisten/Antagonisten und partielle Antagonisten unterteilt werden. Die unterschiedlichen pharmakologischen Eigenschaften der verschiedenen Klassen sind durch ihre Wechselwirkung mit spezifischen Bindungsstellen, den Opioidrezeptoren im Bereich des ZNS zu erklären. Diese Rezeptoren befinden sich besonders in den Strukturen, welche an der Leitung, Verarbeitung sowie der Modulation von schmerzhaften Afferenzen beteiligt sind.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Craig DB (1981) Postoperative recovery of pulmonary function. Anesth Anaig 60: 46–52Google Scholar
  2. 2.
    Spence AA (1980) Postoperative pulmonary complications in general anesthesia. In: Gray TC, Nunn JF, Utting JE (eds), vol 1. Butterworth, London, pp 591–608Google Scholar
  3. 3.
    Bonica JJ (1983) Current status of postoperative pain therapy. In: Yokota T, Dubner R (eds) Current topics in pain research and therapy. Exerpta Medica, Tokio, pp 169–189Google Scholar
  4. 4.
    Modig J (1982) Thromembolism and blood loss: Continuous epidural vs. general anesthesia with v-controlled ventilation. Reg Anesth 7: S84 - S88Google Scholar
  5. 5.
    Cohen FL (1980) Postsurgical pain relief. Patients status and nurses’ medication. Pain 9: 265–274PubMedCrossRefGoogle Scholar
  6. 6.
    Marks RM, Sachar EJ (1973) Undertreatment of medical inpatients with narcotic analgesics. Ann Int Med 78: 173–181PubMedGoogle Scholar
  7. 7.
    Angell M (1982) The quality of mercy. N Engl J Med 306: 98–99PubMedCrossRefGoogle Scholar
  8. 8.
    Sehrt U (1985) Fragwürdiger Analgetikamissbrauch. MMW 127: 825–826Google Scholar
  9. 9.
    Mindach M (2000) Keine Opioidabhängigkeit bei Schmerzpatienten? Schmerz 14: 186–191PubMedCrossRefGoogle Scholar
  10. 10.
    Zimmermann M, Handwerker HO (1984) Schmerz, Konzepte und Ärztliches Handeln. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  11. 11.
    Jurna I (1992) Zentrale Schmerzdämpfung durch peripher wirkende Analgetika. Der Schmerz 6: 61–66PubMedCrossRefGoogle Scholar
  12. 12.
    Rexed B (1964) Some aspects of the cytoarchitectonics and synaptology of the spinal cord. Brain Res 11: 58–92CrossRefGoogle Scholar
  13. 13.
    Yaksh T (1999) Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol Sei 20: 329–337CrossRefGoogle Scholar
  14. 14.
    Goodman RR, Snyder SH (1982) Autoradiographic localization of kappa opiate receptors to deep layers of the cerebral cortex may explain unique sedative and analgesic effects. Life Sei 31: 1291–1294CrossRefGoogle Scholar
  15. 15.
    Yaksh TL (1981) Spinal opiate analgesics. Characteristics and principles of action. Anesthesiology 11: 293–346Google Scholar
  16. 16.
    Yaksh TL, Howe JR (1982) Opiate receptors and their definition by antagonists. Anesthesiology 56: 246–249PubMedCrossRefGoogle Scholar
  17. 17.
    Yaksh TL (1983) In vivo studies on the spinal opiate receptor systems mediating antinociception. I. ju and 5 receptor profiles in the primate. J Pharmacol Exp Ther 226: 303–316PubMedGoogle Scholar
  18. 18.
    Cousins MJ, Cherry DA, Gourlay GK (1988) Acute and chronc pain: use of spinal opioids. In: Cousins MJ, Briden-baugh PO (eds) neural blockade in clinical anesthesia and management of pain. Lippincott, Philadelphia, pp 955–1029Google Scholar
  19. 19.
    Chattipakorn SC, Light AR, Willockson HH, Närhi M, Meix-ner W (1999) The effect of fentanyl on c-fos expression on the trigeminal brainstem complex produced by pulpal heat stimulation in the ferret. Pain 82: 207–215PubMedCrossRefGoogle Scholar
  20. 20.
    Wall PD (1988) The prevention of postoperative pain. Pain 33: 289–290PubMedCrossRefGoogle Scholar
  21. 21.
    Wall PD, Woolf CJ (1986) The brief and prolonged facila-tory effect of unmyelinated afferent input on the rat spinal cord are independently influenced by peripheral nerve section. Neuroscience 17: 1199–11205PubMedCrossRefGoogle Scholar
  22. 22.
    Katz J, Kavanagh BP, Sandler AN et al. (1992) Preemptive analgesia-clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 77: 439–446PubMedCrossRefGoogle Scholar
  23. 23.
    McQuay HJ (1992) Pre-emptive analgesia. Br J Anaesth 66: 1–2CrossRefGoogle Scholar
  24. 24.
    Kleckner NW, Dingledine R (1988) Requirement of glycine in ativation of NMDA receptors expressed in Xenoptus oocytes. Science 241: 835–837PubMedCrossRefGoogle Scholar
  25. 25.
    Maurset A, Moberg ER, Oye I (1990) The analgesic effect of ketamine: Evidence for a non-opioid, PCP receptor mediated mechanism. In: Domino EF (ed) Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp 239–246Google Scholar
  26. 26.
    Smith DJ, Bouchal RL (1981) Ketamine interacts with dysphoric sigma opiate receptors. Anesthesiology 55: A234CrossRefGoogle Scholar
  27. 27.
    Meiler ST, Gebhart GF (1993) Nitric oxide ( NO) and nociceptive processing in the spinal cord. Pain 52: 127–136Google Scholar
  28. 28.
    Przewlocki R, Machelska H, Przewlocka B (1993) Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sei 53: 1–5CrossRefGoogle Scholar
  29. 29.
    Kolesnikov YA, Pick CG, Ciszewska G, Pasternack GW (1993) Blockade of tolerance to morphine but not to k opioids by a nitric oxide synthese inhibitor. Proc Natl Acad Sei USA 90: 5162–5166CrossRefGoogle Scholar
  30. 30.
    Basbaum AI, Fields HL (1984) Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7: 309–338Google Scholar
  31. 31.
    Fields KL, Anderson SD (1978) Evidence that raphe-spinal neurons mediate opiate and midbrain stimulation produced analgesia. Pain 5: 333–349PubMedCrossRefGoogle Scholar
  32. 32.
    Wiklund L, Behzadi G, Kahlen P, Headley PM, Nicolopoulos LS (1988) Autoradiographic and electrophysiological evidence for exicitatory amino acid transmission in the periaqueductal gray projection to nucleus raphe magnus in the rat. Neurosci Lett 93: 158–163PubMedCrossRefGoogle Scholar
  33. 33.
    Urban MO, Smith DJ (1993) Role of neurotensin in the nucleus raphe magnus in opioid-induced antinociception from the periaqueductal gray. J Pharmacol Expt Ther 265: 580–586Google Scholar
  34. 34.
    Melzack R, Wall PC (1965) Pain mechanisms: A new theory. Science 150: 971Google Scholar
  35. 35.
    Zimmermann M (1979) Neurophysiology of nociception, pain and pain therapy. In: Bonica JJ, Ventafridda V (eds) Advances in pain research, vol 2. Raven, New York, pp 13–23Google Scholar
  36. 36.
    Tölle TR, Schadrack J, Castro-Lopes JM, Evan G, Roques BP, Zieglgänsberger W (1994) Effects of kelartorphan and morphine before and after noxious stimulation on immediate-early gene expression in rat spinal cord neurons. Pain 56: 103–112PubMedCrossRefGoogle Scholar
  37. 37.
    Ebersberger A, Anton F, Tolle TR, Zieglgansberger W (1995) Morphine, 5-HT2 and 5-HT3 receptor antagonists reduce c-fos expression in the trigeminal nuclear complex following noxious chemical stmulation of the rat nasal mucosa. Brain Res 676: 336–342PubMedCrossRefGoogle Scholar
  38. 38.
    Kayser V, Fournie-Zaluski MC, Guilbaud G, Roques BP (1989) Potent antinociceptive effects of kelatorphan, a highly efficient inhibitor of multiple enkaphalin-degra-ding enzymes, systemically administered in normal and arthritic rats. Brain Res 497: 94–101PubMedCrossRefGoogle Scholar
  39. 39.
    Hammond DL, Preslez R, Gogas KR, Basaum Al (1992) Morphine or U-50,488H suppresses fos proteine-like immuno-reactivity in the spinal cord and the nucleus tractus solita-rii evoked by noxious visceral stimulus in the rat. J Comp Neurol 315: 244–253PubMedCrossRefGoogle Scholar
  40. 40.
    Higuchi T, Yamazaki O, Takazawa A et al. (1986) Effects of carbamazepine and valporic acid on brain immunore-active somatostatin and gamma-aminobutyric acid in amygdaloid-kindled rats. Eur J Pharmacol 125: 169–175PubMedCrossRefGoogle Scholar
  41. 41.
    Tolle TR, Castro-Lopes JM, Schadrack J, Evan G, Zieglgansberger W (1996) Anticonvulsants suppress c-fos protein expression in spinal cord neurons following noxious thermal stimulation. Expt Neurol 132: 271–278CrossRefGoogle Scholar
  42. 42.
    Sawynok J, La Bella FS (1982) On the involvement of GABA in the analgesia produced by baclofen, muscimol and morphine. Neuropharmacology 21: 397–404PubMedCrossRefGoogle Scholar
  43. 43.
    Castro-Lopes JM, Tolle TR, Pan NB, Ziegelgansberger W (1994) Expression of GRAD mRNA in spinal cord neurons of normal and monoarthritic rats. Mol Brain Res 26: 169–176PubMedCrossRefGoogle Scholar
  44. 44.
    Hammond DL, Drowner EJ (1984) Effects of intrathecal administerd THIP, baclofen and muscimol on nociceptive threshold. Eur J Pharmacol 103: 121–125PubMedCrossRefGoogle Scholar
  45. 45.
    Hao JX, Xu XJ, Yu YX, Seiger A, Wisenfeld-Hallin Z (1992) Baclofen reverses the hypersensitivity of dorsal horn dynamic range neurons to mechanical stimulation after transient spinal cord ischemia: implication for a tonic GABAergic inhibitory control of myelinated fiber input. J Neurophysiol 68: 392–396Google Scholar
  46. 46.
    Aigouy I, Fondras IC, Pajot J, Schoeffler P, Woda A (1992) Intrathecal midazolam vs. intrathecal morphine in orofacial nociception-an experimental study in rats. Neurosci Lett 139: 97–99PubMedCrossRefGoogle Scholar
  47. 47.
    Guilbaud G, Benoist JM, Levante A, Gautron M, Wilier JC (1992) Primary somatosensory cortex in rats with pain-re-lated behaviors due to peripheral mononeuropathy after moderate ligation of one sciatic nerve: neuronal responsi-vity to somatic stimulation. Exp Brain Res 92: 227–245PubMedCrossRefGoogle Scholar
  48. 48.
    Jensen TS, Yaksh TL (1992) Brainstem excitatory amino acid receptors in nociception: mircroinjection mapping and pharmacological characterization of glutamate-sensi-tive sites in brainstem associated with algogenic behavior. Neuroscience 442: 513–526Google Scholar
  49. 49.
    Mc Kenzie JS, Beechy NR (1962) The effects of morphine and pethidine on somatic evoked responses in the midbrain of the cat, and their relevance to analgesia. Electro-enceph Clin Neurophysiol 14: 501–519CrossRefGoogle Scholar
  50. 50.
    Simantov R, Snowman AM, Snyder SH (1976) A morphinelike factor »enkephalin« in rat brain: subcellular localization. Brain Res 107: 650–655PubMedCrossRefGoogle Scholar
  51. 51.
    Hong JS, Yang HY, Fratta W, Costa E (1977) Determination of methionine enkephalin in discrete regions of rat brain. Brain Res 134: 383PubMedCrossRefGoogle Scholar
  52. 52.
    Hassler R (1976) Über die antagonistischen Systeme der Schmerzempfindung und des Schmerzgefühls im peripheren und zentralen Nervensystem. In: Kubicki S, Neuhaus GA (Hrsg) Pentazocin im Spiegel der Entwöhnung. Springer, Berlin Heidelberg New York, pp 1–17Google Scholar
  53. 53.
    Hassler R (1976) Wechselwirkungen zwischen dem System der schnellen Schmerzempfindung und dem des langsamen, nachhaltigen Schmerzgefühl. Arch Klin Chir 342: 47Google Scholar
  54. 54.
    Pert CB, Snyder SH (1973) Opiate receptor: Demonstration in nervous tissue. Science 179: 1011–1014Google Scholar
  55. 55.
    Kuhar MJ, Pert CB, Snyder SH (1973) Regional distribution of opiate receptor binding in monkey and human brain. Nature 245: 447–450PubMedCrossRefGoogle Scholar
  56. 56.
    Delia Bella D, Casacci F, Sassi A (1978) Opiate receptors: Different ligand affinity in various brain regions. Adv Bio-chem Psychopharmacol 18: 271–277Google Scholar
  57. 57.
    Pasternak GW, Wood PJ (1986) Minireview: Multiple mu opiate receptors. Life Sei 38: 1889–1898Google Scholar
  58. 58.
    Pasternak GW (1988) Multiple morphine and enkephalin receptors and the relief of pain. JAMA 259: 1362–1367PubMedCrossRefGoogle Scholar
  59. 59.
    Wood PL, Charlson SE, Laue D, Hudgin RL (1981) Multiple opiate receptors: Differential binding of jn, k and 6 agonists. Neuropharmacology 20: 1215–1220PubMedCrossRefGoogle Scholar
  60. 60.
    Wood PL (1982) Multiple opiate receptors: Support for unique jj, ö and k sites. Neuropharmacology 21: 487–497PubMedCrossRefGoogle Scholar
  61. 61.
    Corbett D, Paterson SJ, Kosterlitz HW (1993) Selectivity of ligands for opioid receptors. In: Herz A (ed) Opioids I. Handbook of experimental pharmacology, vol 104/1. Springer, Berlin Heidelberg New York, pp 645–680Google Scholar
  62. 62.
    Perry DC, Rosenbaum JS, Kursowski M, Sadee W (1982) 3H-Etorphine receptor binding in vivo: Small fractional occupancy elicits analgesia. J Pharmacol Exp Ther 21: 272–279Google Scholar
  63. 63.
    Rosenbaum JS, Holford NHG, Sadee W (1984) Opiate receptor binding-effect relationship: Sufentanil and etor-phine produce analgesia at the ju-site with low fractional receptor occupancy. Brain Res 291: 317–324Google Scholar
  64. 64.
    Sadee W, Richards ML, Grevel J, Rosenbaum SJ (1983) In vivo characterization of four types of opioid binding sites in rat brain. Life Sei 33: 187–189CrossRefGoogle Scholar
  65. 65.
    Freye E (1987) Opioide in der Anästhesiologie. Wirkeffekte und klinische Anwendung. Urban and Schwarzenberg, München Wien BaltimoreGoogle Scholar
  66. 66.
    Raffa RB, Friedrichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an »atypical« opioid analgesic. J Pharmacol Exp Ther 260 /1: 275–285PubMedGoogle Scholar
  67. 67.
    Yanagita T (1978) Drug dependence potential of 1-(m-methoxyphenyl)-2-(-dimethylaminomethyl-cyclohe-xan-1)-hydrochlorid (tramadol) tested in monkeys. Drug Res 28: 159–163Google Scholar
  68. 68.
    Martin WR, Eades GG, Thompson JA, Huppier RE, Gilbert PE (1976) The effects of morphine and nalorphine-like drugs in the non-dependant and morphine-dependant chronic spinal dog. J Pharmacol Exp Ther 197: 517–532PubMedGoogle Scholar
  69. 69.
    Sircar R, Zukin SR (1983) Characterization of specific sigma opiate/phencyclidine ( PCP)-binding sites in the human brain. Life Sei 33: 259–262Google Scholar
  70. 70.
    Finck AD, Nagai SH (1981) Ketamine interacts with opiate receptors in vivo. Anesthesiology 55: A241Google Scholar
  71. 71.
    Finck AD, Nagai SH (1981) Ketamine effects in opiate receptor bioassay. Anesthesiology 55: A242Google Scholar
  72. 72.
    Schmidt WK, Tarn SW, Shotzberger GS, Smith DH, Clark R, Vernier VG (1985) Nalbuphine. Drug Alcohol Depend 14: 339–362CrossRefGoogle Scholar
  73. 73.
    Schaal M, Freye E, Windelschmidt R (1986) Tifluadom, ein Benzodiazepin mit opioidartigem Wirkcharakter: Eine Untersuchung zum zentralen Wirkmechanismus an wachen Hunden. Z EEG-EMG 17: 27–31Google Scholar
  74. 74.
    De Castro J, Andrieu S, Boogaerts J (1982) Buprenorphine. A review of its pharmacological properties and therapeutical uses. De Castro J (ed) New Drug Series, vol 1. Kluwer NVM and ISA, AntwerpenGoogle Scholar
  75. 75.
    Freye E (1987) Opioid Agonists, Antagonists and Mixed Narcotic Analgesics. Theoretical background and considerations for practical use. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  76. 76.
    Romagnoli A, Keats AS (1980) Ceiling effect for respiratory depression by nalbuphine. Clin Pharmacol Ther 27: 478–485PubMedCrossRefGoogle Scholar
  77. 77.
    Dhawan BN, Cesselin F, Raghubir R et al. (1996) International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48: 567–592PubMedGoogle Scholar
  78. 78.
    Noble F, Cox BM (1995) Differential regulation of D1 dopamine receptor and A2a adenosine receptor-stimulated adenyl-cyclase by ¡j, ö1; 52-opioid agonists in rat caudate putamen. J Neurochem 65: 125–133PubMedCrossRefGoogle Scholar
  79. 79.
    Rossi GC, Leventhal L, Pan Y-X et al. (1997) Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6ß-glucuronide antinociception. J Parmacol Expt Ther 281: 109–114Google Scholar
  80. 80.
    Pan YX, Xu J, Bolan E et al. (1999) Indentification and characterization of three new alternatively spliced ju-opioid receptor isoforms. Mol Pharm 56: 396–403Google Scholar
  81. 81.
    Blake AD, Bot G, Reisine T (1996) Structure-function analysis of the cloned opiate receptors. Peptide and small molecule interaction. Chem Biol 3: 967–972Google Scholar
  82. 82.
    Henderson C, McKnight AT (1997) The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ. Trends Pharmacol Sei 18: 293–300CrossRefGoogle Scholar
  83. 83.
    Walker JR, Koob GF (1997) Commentary: orphan anxiety. Proc Natl Acad Sei USA 94: 14217–14219CrossRefGoogle Scholar
  84. 84.
    Nicolson JR, Paterson SJ, Menzies JRW, Corbett AD, McKnight AT (1998) Pharmacological studies on the »orphan« opioid receptor in central and peripheral sites. Can J Physiol Pharmacol 76: 304–313CrossRefGoogle Scholar
  85. 85.
    Jhamandas KH, Sutak M, Henderson G (1998) Antinocicep-tine and morphine modulatory actions of spinal orphanin FQ. Can J Physiol Pharmacol 76: 314–324PubMedCrossRefGoogle Scholar
  86. 86.
    Foote RW, Maurer R (1982) Autoradiographic localization of opiate lat. K-receptors in the guinea pig brain. Eur J Pharmacol 85: 99–103Google Scholar
  87. 87.
    Freye E (1987) Neue Aspekte in der Schmerztherapie mit Opioiden. Anaesthesiol Reanimat 12: 3–17Google Scholar
  88. 88.
    Woolf CJ, Mannion RJ (1999) Neuropathie pain: aetiology, symptoms, mechanisms, and management. Lancet 353: 1959–1964PubMedCrossRefGoogle Scholar
  89. 89.
    Ferreira SH (1981) Prostaglandins, aspirin-like drugs and analgesics. Nature New Biol 240: 200–203Google Scholar
  90. 90.
    Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method of cancer pain relief. Cancer 1987 59: 851–856CrossRefGoogle Scholar
  91. 91.
    Wesselmann U, Burnett AL, Heinberg LJ. The urogenital and rectal pain syndromes. Pain 1997 73: 269–294PubMedCrossRefGoogle Scholar
  92. 92.
    Maier C, Hildebrandt J (1991) Leserbrief zu dem Editorial von M. Zimmermann: Opioide für nicht tumorbedingte chronische Schmerzen. Schmerz 5: 90–91Google Scholar
  93. 93.
    Zech D (1991) Leserbrief zu dem Editorial von M. Zimmermann: Opioide für nicht tumorbedingte chronische Schmerzen? Schmerz 5: 89–90PubMedCrossRefGoogle Scholar
  94. 94.
    Zenz M, Strumpf M, Willweber-Strumpf A (1991) Erwiederungen zu den vorstehenden Leserbriefen von D. Zech, C. Maier und J. Hildebrandt. Schmerz 5: 91–94Google Scholar
  95. 95.
    Zenz M, Strumpf M, Willweber-Strumpf A (1990) Orale Opiattherapie bei Patienten mit »nicht-malignen« Schmerzen. Schmerz 4: 14–21PubMedCrossRefGoogle Scholar
  96. 96.
    Sorge J, Steffmann B, Lehmkuhl C, Pichlmayr I (1991) Opioidanalgetika bei »nichtmalignen «Schmerzen–Lang-zeitbehandlungsergebnisse bei Patienten mit rheumatischen Beschwerden. Schmerz 5: 60–66PubMedCrossRefGoogle Scholar
  97. 97.
    Portenoy RK (1996) Opioid therapy for chronic nonmalig-nant pain: A review of the critical issues. J Pain Symptom Manage 11: 203–217PubMedCrossRefGoogle Scholar
  98. 98.
    Dertwinkel R, Wiebalck A, Zenz M, Strumpf M (1996) Orale Opioide zur Therapie chronischer Nicht-Tumorschmerzen. Anästhesist 45: 495–505CrossRefGoogle Scholar
  99. 99.
    Florez J, Mediavilla A (1978) Respiratory and cardiovascular effects of met-enkephalin applied to the ventral surface of the brain stem. Brain Res 138: 585–590CrossRefGoogle Scholar
  100. 100.
    Ngai SH (1961) The effects of morphine and meperidine on the central respiratory mechanisms in the cat: The action of levallorphan in antagonizing these effects. J Pharmacol Exp Ther 131: 91–102PubMedGoogle Scholar
  101. 101.
    Freye E, Härtung E (1981) Fentanyl in the fourth cerebral ventricle causes respiratory depression in the anesthetized but not in the awake dog. Acta Anaesthesiol Scand 25: 171–173PubMedCrossRefGoogle Scholar
  102. 102.
    Freye E, Härtung E, Kalibe S (1983) Prevention of late fen-tanyl-induced respiratory depression after the injection of the opiate antagonists naltrexone and S-20682 as compared to naloxone. Br J Anaesth 55: 71–77PubMedCrossRefGoogle Scholar
  103. 103.
    Stoeckel H, Hengstmann JH, Schüttler J (1979) Pharmacokinetics of fentanyl as a possible explanation for recurrence of respiratory depression. Br J Anaesth 51: 741PubMedCrossRefGoogle Scholar
  104. 104.
    Freye E, Azevedo L, Härtung E (1985) Reversal of fentanyl-related respiratory depression with nalbuphine; effects on the C02-response curve of man. Acta Anaesthesiol Belg 36: 365–374PubMedGoogle Scholar
  105. 105.
    Magruder MR, DeLaney RD, DiFazio CA (1982) Reversal of narcotic-induced respiratory depression with nalbuphine hydrochloride. Anesthesiol Rev 9: 34–37Google Scholar
  106. 106.
    Clark NJ, Meulemann T, Liu WS, Zwaniken P, Pace NL, Stanley TH (1987) Comparison of sufentanil-N20 and fen-tanyl-N20 in patients without cardiac disease undergoing general surgery. Anesthesiology 66: 130–135PubMedCrossRefGoogle Scholar
  107. 107.
    Bailey PL, Streisand JB, East KA et al. (1990) Differences in magnitude and duration of opioid induced respiratory depression and analgesia with fentanyl and sufentanil. Anesth Analg 70: 8–15PubMedCrossRefGoogle Scholar
  108. 108.
    Meert TF (1995) Mögliche funktionelle Rolle verschiedener Opioidrezeptoren. In: Henschel WF (Hrsg) II. Europäisches Analgesieforum. Urban and Schwarzenberg, München, Wien, Baltimore, pp 18–29Google Scholar
  109. 109.
    Vaught JL, Rothman RB, Westfall TC (1982) Mu and delta receptors: their role in analgesia and in the differential effects of opioid peptides on analgesia. Life Sei 30: 1443–1455CrossRefGoogle Scholar
  110. 110.
    Freye E, Schnitzler M, Schenk G (1991) Opioid-induced respiratory depression and analgesia may be mediated by different subreceptors. Pharm Res 8: 196–199PubMedCrossRefGoogle Scholar
  111. 111.
    Freye E, Latasch L (1992) The opioid ö-reeeptor is involved in respiratory depression. Proceedings International Narcotics Research Conference. Keystone, Colorado, USA, p 147Google Scholar
  112. 112.
    Magnan J, Paterson SJ, Tavani A, Kosterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmie-debergs Arch Pharmacol 319: 197–205CrossRefGoogle Scholar
  113. 113.
    Sofuoglu M, Portoghese PS, Takemori AE (1990) Differential antagonism of delta receptor antagonists by naltrin-dole and its benzufuran analog ( NTB) in mice. Pharmacol Exp Ther 257: 676–680Google Scholar
  114. 114.
    Takemori AE, Portoghese PS (1992) Selective naltrexone-derived opioid receptor antagonists. Annu Rev Pharmacol Toxicol 32: 239–269PubMedCrossRefGoogle Scholar
  115. 115.
    He L, Lee N (1998) Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmacol Exp Ther 285: 1181–1186PubMedGoogle Scholar
  116. 116.
    Hughes MA, Glass PSA, Jacobs JR (1992) Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 76: 334–341PubMedCrossRefGoogle Scholar
  117. 117.
    Egan TD, Lemmens HJM, Fiset P et al. (1992) The pharmacokinetics and pharmacodynamics of GI87084B. Anesthesiology 77/3 A: A369Google Scholar
  118. 118.
    Fink BR (1961) Influence of cerebral activity in wakefulness on regulation of breathing. J Appl Physiol 16: 15–23PubMedGoogle Scholar
  119. 119.
    Sullivan CE, Murphy E, Kozar IE, Philipson EA (1978) Waking and ventilatory responses to laryngeal stimulation in sleeping dogs. J Appl Physiol 45: 681–688PubMedGoogle Scholar
  120. 120.
    Latasch L, Christ R (1991) Respiratory safety. In: Lehmann K, Zech D (eds) Transdermal fentanyl. Springer, Berlin Heidellberg New York Tokio, pp 149–157CrossRefGoogle Scholar
  121. 121.
    De Castro J (1971) Association des analgésiques centraux et des neuroleptiques en cours d’intervention. In: Vourch G, De Castro J, Gauthier-Lafaye P, Guidicelli JF, Viars P (éds) Les analgésiques et la douleur. Influences pharma-cologiques diverses exercées sur morphiniques. Masson, Paris, pp 185–194Google Scholar
  122. 122.
    Becker LD, Paulson BA, Miller RD, Severinghaus FU, Eger El (1976) Biphasic respiratory depression after fentanyl-droperidol or fentanyl alone used to supplement nitrous oxide anesthesia. Anesthesiology 44: 291–296PubMedCrossRefGoogle Scholar
  123. 123.
    Corail IM, Moore AR, Strunin L (1980) Plasma concentrations of fentanyl in normal surgical patients and those with severe renal and hepatic disease. Br J Anaesth 52: 101–110Google Scholar
  124. 124.
    Harper MH, Hickey RF, Cromwell TH, Linword S (1976) The magnitude and the duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man. J Pharmacol Exp Ther 199: 464–455PubMedGoogle Scholar
  125. 125.
    Lehmann KA, Weski C, Hunger L, Heinrich C, Daub D (1982) Biotransformation von Fentanyl. II. Akute Arzneimittelinteraktion - Untersuchungen bei Ratte und Mensch. Anästhesist 31: 221Google Scholar
  126. 126.
    Schaer H, Baasch K, Reist F (1978) Die Atemdepression mit Fentanyl und ihre Antagonisierung mit Naloxon. Anästhesist 27: 259Google Scholar
  127. 127.
    Elstrom J (1977) Plasma protein binding of Phenytoin after cholecystectomy and neurosurgical operations. Acta Neur Scand 55: 455CrossRefGoogle Scholar
  128. 128.
    Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  129. 129.
    MacClain DA, Hug CCJ (1980) Intravenous fentanyl kinetics. Clin Pharmacol Ther 28: 106CrossRefGoogle Scholar
  130. 130.
    Olson GD, Bennett WM, Porter GA (1975) Morphine and Phenytoin binding to human plasma protein in renal and hepatic failure. Clin Pharmacol Ther 17: 677Google Scholar
  131. 131.
    Lehmann KA, Freier J, Daub D (1982) Fentanyl-Pharma-kokinetik und postoperative Atemdepression. Anästhesist 31: 111Google Scholar
  132. 132.
    De Castro J, Viars P (1968) Utilisation pratique des analgésiques centraux en anesthésie et réanimation. Ars Med 23: 1–228Google Scholar
  133. 133.
    Freye E, Härtung E (1993) Kardiovaskuläre und zentralnervöse Effekte unter Fentanyl vs. Sufentanil bei der Intubation herzchirurgischer Patienten. Anästhesie Aktuell 9: 3–14Google Scholar
  134. 134.
    Moruzzi G, Magoun HW (1949) Brain stem reticular formation and activation of the EEG. Electroenceph Clin Neuro-physiol 1: 455–473Google Scholar
  135. 135.
    Akimoto H, Yamaguchi N, Okabe Ki et al. (1956) On the sleep induced through electrical stimulation in dog thalamus. Folia Psychiatr Neurol Jpn 10: 117–146Google Scholar
  136. 136.
    Quock RM, Mueller J (1991) Protection by U-50,488H against ß-chlornaltrexamine antagonism of nitrous oxide antinociception in mice. Brain Res 549: 162–164PubMedCrossRefGoogle Scholar
  137. 137.
    Fink AD, Ngai SH, Berkowitz BA (1977) Antagonism of general anesthesia by naloxone in the rat. Anesthesiology 46: 241–245CrossRefGoogle Scholar
  138. 138.
    Freye E, Härtung E, Schenk GK (1983) Naloxone reverses the hypnotic effect and the depressed baroreceptor reflex of halothane-anaesthesia in the dog. Can Anaesth Soc J 8: 235–241CrossRefGoogle Scholar
  139. 139.
    Römer D, Büscher H, Hill RC et al. (1980) Bremazocine: A potent, long-acting opiate kappa-agonist. Life Sei 27: 971–978CrossRefGoogle Scholar
  140. 140.
    Freye E, Härtung E, Schenk GK (1983) Bremazocine: An opiate which induces sedation and analgesia but no respiratory depression. Anesth Analg 62: 483–488Google Scholar
  141. 141.
    Freye E, Boeck A, Ciramelli F (1986) The benzodiazepine (+)tifluadom (KC-6128) and not its optical isomer (KC-5911) induces opioid kappa-receptor related EEG power spectra and evoked potential changes. Pharmacology 33: 241–248PubMedCrossRefGoogle Scholar
  142. 142.
    Von Voigtlander PF, Lahti RA, Ludeus JH (1983) U-50,488H: A seletive and structurally novel non-mu (kappa) agonist. J Pharmacol Exp Ther 224: 7–12Google Scholar
  143. 143.
    Maurer R, Cortes R, Probst A, Palacios JM (1983) Multiple opiate receptors in human brain. Life Sei 17: 231–234CrossRefGoogle Scholar
  144. 144.
    Wevers A, Schmidt P, Cserpan E et al. (1995) Cellular distribution of the mRNA for the K-opiod receptor in the human neocortex: a non-isotopic in situ hybridization study. Neurosci Lett 195: 1–4CrossRefGoogle Scholar
  145. 145.
    Wood PL (1984) k Agonists Analgesics: Evidence for \\2 and 6 opioid receptor antagonism. Drug Dev Res 4: 429–435Google Scholar
  146. 146.
    Wood PL, Sanschagrin D, Richard JW, Thakur M (1983) Multiple opiate receptor affinities of kappa and agonist/ antagonist analgesics: in vivo assessment. J Pharmacol Expt Ther 226: 545–550Google Scholar
  147. 147.
    Cheng EY, May J (1989) Nalbuphine reversal of respiratory depression after epidural sufentanil. Crit Care Med 17: 378–379PubMedCrossRefGoogle Scholar
  148. 148.
    Pfeiffer A, Pasi A, Mehrain P, Herz A (1982) Opiate receptor binding sites in human brain. Brain Res 248: 87–96PubMedCrossRefGoogle Scholar
  149. 149.
    Di Fiazo CA, Moscicki JC, Magruder MR (1981) Anesthetic potency of nalbuphine and interaction with morphine in rats. Anesth Analg 60: 629–622Google Scholar
  150. 150.
    Dumas PA (1984) MAC reduction of enflurane and isoflu-rane and postoperative findings with nalbuphine HCl and fentanyl: A retrospective study. In: Gomez QJ (ed) VI Ith World Congress of Anaesthesiologists. Manila/Philippines: Exerpta Medica, Amsterdam, pp 43–53Google Scholar
  151. 151.
    Murphy MR, Hug CC (1982) The enflurane sparing effect of morphine, butorphanol, and nalbuphine. Anesthesiology 57: 489–492PubMedCrossRefGoogle Scholar
  152. 152.
    Ghoneim MM, Dhanarrj J, Choi WW (1984) Comparison of four opiod analgesics as supplements to nitrous oxide analgesia. Anesth Analg 63: 405–412PubMedCrossRefGoogle Scholar
  153. 153.
    Bovill JG, Sebel PS, Wauquier A, Rog P (1982) Electroence-phalographic effects of sufentanil anaesthesia in man. Br J Anaesth 54: 45–52PubMedCrossRefGoogle Scholar
  154. 154.
    Smith NT, Dec-Siilver H, Sanford TJ et al. (1984) EEGs during high-dose fentanyl, sufentanil-, or morphine-oxygen anesthesia. Anesth Analg 63: 386PubMedGoogle Scholar
  155. 155.
    Freye E, Schinagel A, Härtung E (1985) EEG-Powerspektren und Plasmakonzen trationen von Alfentanil. In: Zindler M, Härtung E (Hrsg) Alfentanil–Ein neues, ultra kurzwirkendes Opioid. Urban and Schwarzenberg, München Wien Baltimore, pp 45–51Google Scholar
  156. 156.
    Bovill JG, Sebel S, Wauquier A, Rog P (1982) Electroence-phalographic effects of sufentanil anaesthesia in man. Br J Anaesth 54: 45–52PubMedCrossRefGoogle Scholar
  157. 157.
    Bovill JG, Sebel S, Wauquier A, Rog P, Schuyt HC (1983) The influence of high dose alfentanil anaesthesia on the electroencephalogram: Correlation with plasma concentrations. Br J Anaesth 55: 199 S-209 SGoogle Scholar
  158. 158.
    Scott JC, Ponganis KV, Stanski DR (1985) EEG quantification of narcotic effect: The comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 62: 234–241Google Scholar
  159. 159.
    Souza EB, Schmidt WK, Kuhar MJ (1987) Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system on an agonist/antagonist analgesic. J Pharmacol Expt Ther 244: 391–402Google Scholar
  160. 160.
    Herz A, Teschemacher HJ (1971) Activities and site of antinociceptive action of morphine-like analgesics. Adv Drug Res 6: 79–119Google Scholar
  161. 161.
    Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) Pharmacological profile of ritanerin: a very specific central serotonin S2-antagonist. Drug Dev Res 15: 61–73CrossRefGoogle Scholar
  162. 162.
    Leysen JE, Gommeren W, Niemegeers CJE (1983) 3H-su-fentanil, a superior ligand for the mu-opiate receptor: Binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol 87: 209–225Google Scholar
  163. 163.
    Niemegeers CJE, Janssen PAJ (1981) Alfentanil (R 39 209)-a particularly short-acting narcotic analgesic in rats. Drug Dev Res 1: 83–88CrossRefGoogle Scholar
  164. 164.
    Van Bever WFM, Niemegeers C, Janssen P, Van Ree J (1978) N-4-substituted1 -(2arylethyl)-4-piperidinyl-N-phe-nylpropanamides, a novel series of extremely potent analgesics with unusually high safety margin. Arzneimittel-forsch/Drug Res 26: 1548–1551Google Scholar
  165. 165.
    Nilsson E, Ingvar DH (1967) EEG findings in neuroleptanalgesia. Acta Anaesth Scand 11: 121–127PubMedCrossRefGoogle Scholar
  166. 166.
    Ingvar DH, Nilsson E (1961) Central nervous effects of neuroleptanalgesia as induced by haloperidol and phen-operidine. Acta anaesth Scand 5: 85–88PubMedCrossRefGoogle Scholar
  167. 167.
    Kubicki S, P. Z. (1966) EEG-Veränderungen durch Neuro-leptanalgesie. Anästh Wiederbelebg 9: 44–49Google Scholar
  168. 168.
    Kubicki S, Stölzel R, Otten J, Hass J (1970) Exzitatorische und inhibitorische Phänomene am Zentralnervensystem, verursacht durch Fentanyl. In: Henschel WF (Hrsg) Neue Klinische Aspekte der Neuroleptanalgesie. Schattauer, Stuttgart New York, pp 21–30Google Scholar
  169. 169.
    Hassler R (1972) Über die Zweiteilung der Schmerzempfindung und des Schmerzgefühl. In: Janzen R, Keidel WD, Herz A, Steichele C (Hrsg) Schmerz. Thieme, Stuttgart, p 105Google Scholar
  170. 170.
    Freye E (1982) Opiatrezeptoren im Gehirn. Perimed Fachbuchverlagsgesellschaft, ErlangenGoogle Scholar
  171. 171.
    Freye E, Arndt JO (1979) Perfusion of the fourth cerebral ventricle with fentanyl induces naloxone reversible hypotension, bradycardia, baroreflex depression and sleep in unanaesthetized dogs. Naunyn-Schmiedebergs Arch Pharmacol 307: 123–128PubMedCrossRefGoogle Scholar
  172. 172.
    Lord JAH, Waterfield AS, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267: 495–499PubMedCrossRefGoogle Scholar
  173. 173.
    Smith TW, Hughes J, Kosterlitz HW, Sosa RP (1976) Enkephalins: Isolation, distribution and function. In: Kosterlitz HW (Ed) Opiates and Endogenous Opioid Peptides. Elsevier, Amsterdam, pp 57–62Google Scholar
  174. 174.
    Czontos DL, Helmne RD (1983) Enkephalins and endorphins; clinical pharmacological and therapeutic implications. Drugs 26: 503–519CrossRefGoogle Scholar
  175. 175.
    Freye E, Schenk GK (1982) Die praktische Bedeutung endogener Opioide ( Endorphine ). Anästhesiol Intensiv-med 23: 280–290Google Scholar
  176. 176.
    Holaday JW, D’Amatao RJ (1983) Multiple opioid receptors: evidence for mu-delta binding site interactions in endotoxic shock. Life Sei 33: 703–706CrossRefGoogle Scholar
  177. 177.
    Long JB, Ruvio BA, Holaday JW (1984) ICI 174,864, a novel delta antagonist, reverses endotoxic shock: Pretreatment with dynorphin (1–13) a kappa agonist, blocks this therapeutic effect. Neuropeptides 5: 292–294CrossRefGoogle Scholar
  178. 178.
    Loh HH, Smith AP (1990) Molecular characterzation of opioid receptors. Annu Rev Pharmacol Toxicol 30: 123–147PubMedCrossRefGoogle Scholar
  179. 179.
    Uhl GR, Childers S, Pasternack GW (1994) An opiate receptor gene family reunion. Trends Neurosci 17: 89–93PubMedCrossRefGoogle Scholar
  180. 180.
    Freye E (1999) Opioide in der Medizin, 4. Aufl. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  181. 181.
    Tam S (1985) (+)-[3H]SKF 10,047, (+)-[3H]ethylketocycla-zocine, jli, k, 5 and phencyclidine binding sites in guinea pig brain membranes. Eur J Pharmacol 109: 33–41CrossRefGoogle Scholar
  182. 182.
    Cookson RF (1983) Carfentanil and Lofentanil. Clin Anaesthesin 1: 156–158Google Scholar
  183. 183.
    Ricaurte GA, Matello AL, Katz JL, Martello MB (1992) Long lasting effects of (±)-3,4-methylenedioxyamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616–622PubMedGoogle Scholar
  184. 184.
    Sanford TJ, Smith NT, Dec-Silver H, Harrison WK (1986) A comparison of morphine, fentanyl, and sufentanil anesthesia for cardiac surgery: Intubation emergence, and extubation. Anesth Analg 65: 259–266Google Scholar
  185. 185.
    Smith NT, Dec-Silver H, Harrison WK, Sanford TJ, Gilling JA (1982) A comparison among morphine, fentanyl and sufentanil anesthesia for open-heart surgery: Induction, emergence and extubation. Anesthesiology 57: A291Google Scholar
  186. 186.
    De Castro J, Van de Water A, Wouters L, Xhonneux R, Reneman R, Kay B (1979) Comparative study of cardiovascular, neurological, and metabolic side effects of eight narcotics in dogs. Acta Anaesth Belg 30: 5–99PubMedGoogle Scholar
  187. 187.
    Hoten AO (1983) Another case of grand mal seizure after fentanyl aministration. Anesthesiology 60: 387–388Google Scholar
  188. 188.
    Goroszeniuk I, Malagosia A, Jones RM (1986) Genralized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia. Anesth Analg 65: 979–981PubMedCrossRefGoogle Scholar
  189. 189.
    Brian JE, Seiten AB (1987) Tonic-clonic activity after sufentanil. Anesth Analg 56: 329Google Scholar
  190. 190.
    Scott JC, Sarnquist FH (1983) Seizure-like movements during fentanyl infusion with absence of seizure activity in a simultaneous EEG recording. Anesthesiology 62: 812–814CrossRefGoogle Scholar
  191. 191.
    Carlsson C, D.S. S„ Kevkhah M, Engelbach I, Harp IR (1982) The effects of high-dose fentanyl on cerebral circulation and metabolism in rats. Anesthesiology 57: 375–380Google Scholar
  192. 192.
    Jaffe JH, Martin WR (1990) Opioid analgesics and antagonists. In: Gilman AF, Goodman LS, Rail TW, Murad F (eds) Goodman and Gilman’s. »The pharmacological basis of therapeutics«, vol 7. Macmillan, New York, pp 491–531Google Scholar
  193. 193.
    Kugler J, Grote B, Laub M, Doenicke A, Dick E (1977) Die hypnotische Wirkung von Fentanyl und Sufentanil. Anästhesist 26: 343–348Google Scholar
  194. 194.
    Chau TT, Carter FE, Harris LS (1982) 3H-codeine binding in the guinea pig lower brain stem. Pharmacology 25: 12–17Google Scholar
  195. 195.
    Heel RC, Brodgen RN, Speight TM, Avery GS (1979) Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17: 81–100Google Scholar
  196. 196.
    Pircio AW, Gylys JA, Cavanagh RL (1976) The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch Int Pharmacodyn Ther 220: 231–257PubMedGoogle Scholar
  197. 197.
    Christiani E, Stübing G (1972) Drogenmissbrauch und Drogenabhängigkeit. Deutscher Ärzteverlag, KölnGoogle Scholar
  198. 198.
    Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs. In: Martin WR (ed) Drug addiction, vol 1. Springer, Berlin Heidelberg New York, pp 197–258CrossRefGoogle Scholar
  199. 199.
    Jasinski DR, Pevnik JS, Griffith JD (1978) Human pharmacology and the abuse potential of the analgesic bupre-norphine. Arch Gen Psychiatry 35: 501–516PubMedCrossRefGoogle Scholar
  200. 200.
    Lewis JW, Walter D (1992) Buprenorphine-background to its development as a treatment for opioid dependence. NIDA Res Monogr 121: 5–11PubMedGoogle Scholar
  201. 201.
    Abbott A (1992) Neurobiological perspectives on drugs of abuse. Trends Pharmacol Sei 13: 169CrossRefGoogle Scholar
  202. 202.
    DiChiara G, Imperato A (1988) Opposite effects of ¡j and k opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244 /3: 1067–1080Google Scholar
  203. 203.
    Ramsey NF, van Ree JM (1992) Reward and abuse of opiates. Pharmacol Toxicol 71 /2: 81–94PubMedCrossRefGoogle Scholar
  204. 204.
    Cherny Nl, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen. Teil 1: Eigenschaften von Nichtopioiden und Opioiden. Schmerz 8: 195–209Google Scholar
  205. 205.
    Rommelspacher H (1981) Zur Frage des Abhängigkeitspotentials und des Mißbrauchs von Pentazocin. In: Kubi-cki S, Neuhaus GA (Hrsg) Pentazocin im Spiegel der Erfahrungen. Springer, Berlin Heidelberg New York, pp 58–63Google Scholar
  206. 206.
    Twycross RG (1988) Opioid analgesics in cancer pain: current practice and controversies. Cancer Surg 7: 29–53Google Scholar
  207. 207.
    Lehmann KA (1988) Analgosedierung mit Opioiden. In: Schulte am Esch J, Benzer H (Hrsg) Analgosedierung des Intensivpatienten. Springer, Berlin Heidelberg New York Tokio, pp 14–34 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 200 )Google Scholar
  208. 208.
    Martin WR, Jasinski DR (1977) Assessment of the abuse potential of narcotic analgesics in animal. In: Martin WR (ed) Drug addiction. I: Morphine, sedative/hypnotic and alcohol dependence. Springer, Berlin Heidelberg New York, p 159 (Handbook of experimental pharmacology, vol 45/I)Google Scholar
  209. 209.
    Houde RW, Wallenstein SL (1955) Report of analgesic studies at Memorial Center: Chlorpromazine potentiation, nalorphine-morphine combinations, dihydro-hydroxy- morphine. National Academy of Sciences, Washington. Bulletin of the 15th Meeting N. A. S. NCR Committee on Drug Addiction and Narcotics, pp 1134–1149Google Scholar
  210. 210.
    Dole VP, Nyswander ME (1965) A medical treatment for diacethylmorphine (heroin-)addiction. JAMA 193: 646–650PubMedCrossRefGoogle Scholar
  211. 211.
    Benos J (1983) Ein Fall von sekundärer Buprenorphin- (Temgesic-)Abhängigkeit. Nervenarzt 54: 259–261PubMedGoogle Scholar
  212. 212.
    Rosow CE (1984) Sufentanil citrate: A new opioid analgesic for use in anesthesia. Pharmacotherapy 4: 111–119Google Scholar
  213. 213.
    Sadee W, Wang Z (1993) Constitutive mu opioid receptor activation can account for narcotic tolerance and dependence. International Narcotics Research Conference (INRC). Uppsala Universitet Reprocentralen HSC, Skövde Sweden, p 102Google Scholar
  214. 214.
    Piepenbrock S, Hempelmann G, Peters H (1977) Veränderungen der Hämodynamik der Herzinotropie und des myocardialen Sauerstoffverbrauchs nach Antagonisie rung von hohen Dosen von Fentanyl mit Naloxon. Prakt Anästh 12: 275Google Scholar
  215. 215.
    Freye E, Härtung E (1982) Naloxone induces excitation of the cardiovascular system and a rise in myocardial oxygen consumption in fentanyl and meperidine-anesthetized dogs. Acta Anaesth Belg 33: 89–97PubMedGoogle Scholar
  216. 216.
    Freye E (1976) Tyrosine hydroxylation in the rat striatum after fentanyl and droperidol in vivo. Expt Brain Res 26: 541–545Google Scholar
  217. 217.
    Goldstein DB, Goldstein A (1961) Possible role of enzyme inhibition and repression in drug tolerance and addiction. Biochem Pharmac 8: 48–53CrossRefGoogle Scholar
  218. 218.
    Scuderi P, Wetchler B, Sung Y-F et al. (1993) Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology 78 /1: 15–20PubMedCrossRefGoogle Scholar
  219. 219.
    McKenzie R, Kovac A, O’Connor T et al. (1993) Comparison of ondansetron vs. placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology 78: 21–28PubMedCrossRefGoogle Scholar
  220. 220.
    Apfel CC, Greim A, Goepfert C et al. (1998) Postoperatives Erbrechen-Ein Score zur Voraussage des Erbrechensrisikos nach Inhalationsanästhesien. Anästhesist 47: 732–740CrossRefGoogle Scholar
  221. 221.
    Sneyed JR, Carr A, Byrom WD, Bilski AJT (1998) A metaanalysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhational agents. Eur J Anaesth 15: 433–445Google Scholar
  222. 222.
    Freund FG, Martin WE, Wong KC, Hornbein TF (1973) Abdominal muscular rigidity induced by morphine and nitrous oxide. Anesthesiology 38: 358PubMedCrossRefGoogle Scholar
  223. 223.
    Sokoll MD, Hoyt JL, Georgids SD (1972) Studies in mucular rigidity, nitrous oxide and narcotic analgesic agents. Anesth Analg 51: 16PubMedCrossRefGoogle Scholar
  224. 224.
    Kuschinsky K, Hornykiewicz O (1972) Morphine katalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19: 119PubMedCrossRefGoogle Scholar
  225. 225.
    Freye E, Kuschinsky K (1976) The effect of fentanyl and droperidol on the dopamine metabolism of the rat striatum. Pharmacology 14: 1–7PubMedCrossRefGoogle Scholar
  226. 226.
    Amalric M, Blasco TA, Smith NT, Lee DL, Swerdlow NR, Koob GF (1986) »Catatonia« produced by alfentanil is reversed by methylnaloxonium microinjections into the brain. Brain Res 386: 287–295Google Scholar
  227. 227.
    Jaffe TB, Ramsey FM (1983) Attenuation of fentanyl-induced truncal rigidity. Anesthesiology 58: 562PubMedCrossRefGoogle Scholar
  228. 228.
    Freye E, Härtung E, Buhl R (1986) Die Lungencompliance wird durch die rasche Injektion von Alfentanil beeinträchtigt. Anästhesist 35: 543–546Google Scholar
  229. 229.
    Weinger MB, Segal IS, Maze M (1991) Dexmedetomidine, acting through central alpha2-adrenoceptors, prevents opiate-induced muscle rigidity in the rat. Anesthesiology 71: 242–249CrossRefGoogle Scholar
  230. 230.
    Paakkari P, Feuerstein G (1988) Antagonism of der-morphin-induced catalepsy with naloxone, TRH-analog CG3703 and the benzodiazepine antagonist, Ro 15–1788. Neuropharmacology 27 /10: 1007–1012PubMedCrossRefGoogle Scholar
  231. 231.
    Illes P, Jurna I, Kaever V, Resch K (1996) Opioidanalgetika. In: Forth W, Henschler D, Rummel W, Starke K (Hrsg) Allgemeine und Spezielle Pharmakologie und Toxikologie, 7. Aufl. Akademischer Verlag, Heidelberg Berlin Oxford, pp 207–214Google Scholar
  232. 232.
    Kromer W (1993) Gastrointestinal effects of opioids. In: Herz A (ed) Opioids II,. Springer, Berlin Heidelberg New York, pp 163–190 (Handbook of experimental pharmacology, vol 104/11)Google Scholar
  233. 233.
    Champion SE, Sullivan SN, Chamberlain M, Vezina W (1982) Naloxone and morphine inhibit gastric emptying of solids. Can J Physiol Pharmacol 60: 732–734PubMedCrossRefGoogle Scholar
  234. 234.
    Dingledine R, Goldstein A (1976) Effect of synaptic transmission blockade on morphine action in the guinea pig myenteric plexus. J Pharmacol Exp Ther 196: 97–106PubMedGoogle Scholar
  235. 235.
    Polak JM, Sullivan SN, Bloom SR, Facer P, Pearse AGE (1977) Enkephalin-like immuno reactivity in the human gastrointestinal tract. Lancet 1: 972–974PubMedCrossRefGoogle Scholar
  236. 236.
    Ambinder RF, Schuster MM (1979) Endorphins: new gut peptides with a familiar face. Gastroenterology 77: 1132PubMedGoogle Scholar
  237. 237.
    Dashwood MR, Debnan ES, Bednall J, Thompson CS (1985) Autoradiographic localisation of opiate receptors in rat small intestine. Eur J Pharmacol 107: 267PubMedCrossRefGoogle Scholar
  238. 238.
    North RA, Williams JT (1975) Enkephalines inhibit fireing of myenteric neurons. Nature 246: 460Google Scholar
  239. 239.
    Sahai KK, Hymson DL, Shapiro R (1978) The mode of actions of enkephalins in the guinea-pig ileum. Neurosci Lett 10: 317CrossRefGoogle Scholar
  240. 240.
    Nimmo WS (1984) Effect of anaesthesia on gastric motility and emptying. Br J Anaesth 56: 29PubMedCrossRefGoogle Scholar
  241. 241.
    Ward SJ, Takemori AE (1983) Relative envolvement of receptor subtypes in opioid-induced inhibition of gastrointestinal transit in mice. J Pharmacol Exp Ther 224: 359–363PubMedGoogle Scholar
  242. 242.
    Tavani A, Bianchi G, Ferreti P, Manara L (1980) Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sei 27: 2211CrossRefGoogle Scholar
  243. 243.
    Manara L, Bianchi G, Ferretti P, Tavani A (1986) Inhibition of gastrointestinal transit by morphine in rats results pri-marely from direct drug action on gut opioid sites. J Pharmacol Exp Ther 237: 945–949PubMedGoogle Scholar
  244. 244.
    Daniel EE, Sutherland WH, Bogoch A (1959) Effects of morphine and other drugs on motility of the terminal ileum. Gastroenterology 36: 510–523PubMedGoogle Scholar
  245. 245.
    Hirning LD, Porreca F, Burks TF (1985) Mu, but not kappa opioid agonists induce contractions of the canine small intestine in vivo. Eur J Pharmacol 109: 49–54PubMedCrossRefGoogle Scholar
  246. 246.
    Monferini E, Strada D, Manara L (1981) Evidence for opiate receptor binding in rat small intestine. Life Sci 29: 595–602PubMedCrossRefGoogle Scholar
  247. 247.
    Terenius L (1972) Specific uptake of narcotic analgesics by subcellular fractions of the guinea pig ileum. Acta Pharmacol Toxicol 31: 50Google Scholar
  248. 248.
    Vater M, Aitkenhead AR (1985) Effect of morphine on gastric emptying. Anaesthesia 40: 81–82PubMedCrossRefGoogle Scholar
  249. 249.
    Park GR, Weir DA (1985) A comparison of the effect of oral controlled release morphine and intramuscular morphine on gastric emptying. Anaesthesia 39: 645–648Google Scholar
  250. 250.
    Ingram DM, Sheiner HJ (1981) Postoperative gastric emptying. Br J Surg 68: 572–576PubMedCrossRefGoogle Scholar
  251. 251.
    Yuan CS (1996) Gastric effects of ju-7 5 and K-opioid receptor agonists on brainstem unitary responses in the neonatal rat. Eur J Pharmacol 314: 27–32PubMedCrossRefGoogle Scholar
  252. 252.
    Folwaczny C, Hundegger K, Volger C et al. (1995) Measurement of transit disorders in different gastrointestinal segments of patients with diabetis mellitus in relation to duration and severity of the disease by use of metal-detector test. Z. Gastroenterol 33: 517–526PubMedGoogle Scholar
  253. 253.
    Wienbeck M, Korner MM (1981) Influence of opiates on colonic motility. Clin Res Rev 1: 199–204Google Scholar
  254. 254.
    Wienbeck M, Blasberg M (1986) Effect of an enkephalin analog on motility of the small and the large intestine in the cat. Z Gastroenterology 24: 179–187Google Scholar
  255. 255.
    Yee MK, Evans WD, Facey PE, Hayward WJ, Rosen M (1991) Gastric emptying and small bowel transit in male vol-unters after i.m. ketorolac and morphine. Br J Anaesth 67: 426–431PubMedCrossRefGoogle Scholar
  256. 256.
    Nimmo WS, Wilson J, Prescott LF (1975) Narcotic analgesics and delayed gastric emptying during labour. Lancet I: 890–893Google Scholar
  257. 257.
    Yukioka H, Rosen M, Evans KT, Leach KG, Hayward MWJ, Saggu GS (1987) Gastric emptying and small bowel transit time in volunteers after intravenous morphine and nalbuphine. Anaesthesia 42: 704–710PubMedCrossRefGoogle Scholar
  258. 258.
    Portenoy RK (1987) Constipation in the cancer patients: Causes and management. Med Clin North Am 71: 303–311PubMedGoogle Scholar
  259. 259.
    Feritti P, Tavani A, Manara L (1981) Inhibition of gastrointestinal transit and antinociceptive effects of morphine and FK 33–824 in rats are differently prevented by naloxone and the N-methyl quarternary analog. Res Commun Subst Abuse 2: 1–11Google Scholar
  260. 260.
    Culpepper-Morgan JA, Inturrisi CE, Portenoy RK et al. (1992) Treatment of opioid-induced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 52: 90–95Google Scholar
  261. 261.
    Yuan CS, Foss JF, O’Connor M, Toledano A, Roizen MF, Moss J (1996) Methylnaltrexone prevents morphine-induced delay on oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59: 469–475Google Scholar
  262. 262.
    Latasch L, Jurna I, Zimmermann M (1996) Opioid constipation: The antagonization of opioid-induced obstipation by naloxone. Dolor 11 (Suppl 1): 47Google Scholar
  263. 263.
    Robinson BA, Johansson L, Shaw J (1991) Oral naloxone in opioid-associated constipation. Lancet 338: 581–582PubMedCrossRefGoogle Scholar
  264. 264.
    Jurna I, Jurna K, Baldauf J, Zenz M (1996) Orales Papave-rin reduziert die morphinbedingte Obstipation ohne Abschwachung der Analgesie nach oralem Morphin. Schmerz 10: 27–35PubMedCrossRefGoogle Scholar
  265. 265.
    Rüssel J, Bass P, Goldberg LI, Schuster CR, Herz H (1982) Antagonism of gut, but not central effects of morphine with quarternary narcotic antagonists. Eur J Pharmacol 78: 255–261CrossRefGoogle Scholar
  266. 266.
    Dragonetti M, Bianchetti A, Sacilotto R et al. (1983) Leval-loprhan methyl iodide (SR 58002), a potent narcotic antgonist with peripheral selectivity superior to that of other quarternary compounds. Life Sci 33 (Suppl 1): 477–480PubMedCrossRefGoogle Scholar
  267. 267.
    Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J (1997) The safety and efficacy of oral methalnaltrexone in preventing morphine-induced delay in oral cecal transit time. Clin Pharmacol Ther 61: 1–9CrossRefGoogle Scholar
  268. 268.
    Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J (2000) Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomisesd controlled trial. JAMA 283: 367–372PubMedCrossRefGoogle Scholar
  269. 269.
    Freye E, Rosenkranz B, Neruda B (1996) Die obstipierende Wirkung der Opioide Tilidin-N und Tramadol im Vergleich zu Codein. Eine vergleichende Gegenüberstellung zweier Wirkstoffkonzentrationen bei Probanden. Schmerz 10: 254–2. 60Google Scholar
  270. 270.
    Wilder-Smith CH, Bettiga A (1997) The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 43: 1–5CrossRefGoogle Scholar
  271. 271.
    Hennies HH, Friedrichs E, Schneider J (1988) Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Drug Res 38 /7: 877–880Google Scholar
  272. 272.
    Jage J, Jurna I (1993) Opioidanalgetika. In: Zenz M, I. J. (Hrsg) Lehrbuch der Schmerztherapie. Wiss. Verlagsges., Stuttgart, pp 137–153Google Scholar
  273. 273.
    Burks TF (1978) Gastrointestinal pharmacology. Ann Rev Pharmacol Toxicol 16: 15–31Google Scholar
  274. 274.
    Shook JE, Pelton JT, Hruby VJ, Burks TF (1987) Peptide opioid antagonist seperates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 243: 492–500PubMedGoogle Scholar
  275. 275.
    Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestnal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230: 341–348PubMedGoogle Scholar
  276. 276.
    Culpepper-Morgan J, Kreek MJ, Holt PR, LaRoche D, Zhang J, O’Bryan L (1988) Orally administered kappa as well as mu opiate agonists delay gastrointestinal transit time in the guinea pig. Life Sci 42: 2073–2077PubMedCrossRefGoogle Scholar
  277. 277.
    Wong CL (1984) The effects of morphine and nalbuphine on intestinal transit in mice. Meth and Find Exptl Clin Pharmacol 6: 685–689Google Scholar
  278. 278.
    Freye E, Knüfermann V (1991) Die gastro-coekale Transitzeit nach Fentanyl/Midazolam-im Vergleich zur Enfluran-und Ketamin/Midazolam-Narkose. Anästhesist 40 (Suppl 2): S 264Google Scholar
  279. 279.
    Niemegeers CJE, Schellenkens KHL, van Bever WFM, Janssen PAJ (1976) Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs. Arzneimittelforsch/Drug Res 216: 1551–1556Google Scholar
  280. 280.
    Lagler F, Helm F, Etzel V, Kiel H (1978) Toxikologische Untersuchungen mit Tramadol, einem neuen Analgetikum. Arzneimittelforsch/Drug Res 28/I: 164–172Google Scholar
  281. 281.
    Janssen PAJ (1984) The development of new synthetic narcotics. In: Estafanous FG (ed) Opioids in anesthesia. Butterworth, Boston, pp 37–44Google Scholar
  282. 282.
    Janssen PAJ, Niemegeers CJE, Schellekens KHL, Lenarts FM (1971) Etomidate (R 16659) a potent short acting and relatively atoxic intravenous hypnotic agent in rats. Drug Res 21: 1234Google Scholar
  283. 283.
    Lewis JW, Ranee MJ, Sanger DJ (1983) The pharmacology and the abuse potential of buprenorphine. JAI Press, pp 103–154 (Advances in Substance Abuse, vol 3 )Google Scholar
  284. 284.
    Meert TF (1989) Pharmacological effects of epidural opioids. Therapeutics Today: Epidural Use of a new opioid: Sufentanil. Adis Press, Hong Kong, pp 1–9Google Scholar
  285. 285.
    De Castro J (1975) Nouveaux morphiniques, morphinoi-des, potentialisateurs et antidotes des morphiniques. Edition Academica, BruxellesGoogle Scholar
  286. 286.
    Laubie M, Schmitt H, Vincent M, Remond G (1977) Central cardiovascular effects of morphinominetic peptides in dogs. Eur J Pharmacol 46: 76–71CrossRefGoogle Scholar
  287. 287.
    Freye E (1974) Cardiovascular effects of high doses of fentanyl, meperidine and naloxone in dogs. Anesth Analg 53: 40–47PubMedCrossRefGoogle Scholar
  288. 288.
    Lappas DG, Geha D, Fischer JE, Laver MB, Lowenstein E (1975) Filling pressures of the heart and pulmonary circulation of the patient with coronary artery disease after large doses of morphine. Anesthesiology 42: 153PubMedCrossRefGoogle Scholar
  289. 289.
    Braunwald E (1971) Control of myocardial oxygen consumption. Am J Cardiol 27: 416PubMedCrossRefGoogle Scholar
  290. 290.
    Stahl KD, Simon EJ (1977) Receptor affinity and pharmacological potency of a series of narcotic analgesics, anti-diarrheal and neuroleptic drugs. Eur J Pharmacol 46: 199–205PubMedCrossRefGoogle Scholar
  291. 291.
    De Lange S, Boscoe MJ, Stanley TH, Pace N (1982) Comparison of sufentanil-02 and fentanyl-02 for coronary artery surgery. Anesthesiology 56: 112–118PubMedCrossRefGoogle Scholar
  292. 292.
    Stephan H, Sonntag H, Lange H, Lüpke K (1989) Die Wirkungen von Sufentanil in hohen Dosen auf die Hämodynamik und die elektroenezephalographische Aktivität von Koronarkranken. Anästhesist 38: 510–518Google Scholar
  293. 293.
    Zola EM, MacLeod DC (1983) Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intel! Clin Pharm 17: 411–417Google Scholar
  294. 294.
    Dick W (1981) Möglichkeiten und Probleme der postoperativen Schmerzbekämpfung. Anästhesiol Intensivmed 2: 38–44Google Scholar
  295. 295.
    Boldt J, Kling D, von Bormann B, Knoblauch K, Görlach G, Hempelmann G (1987) Meptazinol, ein neuartiges Analgetikum. Anästhesist 36: 622–628Google Scholar
  296. 296.
    Strauer BE (1972) Contractile responses to morphine, piri-tramid and fentanyl: a comparative study of effects on the isolated myocardium. Anesthesiology 37: 304PubMedCrossRefGoogle Scholar
  297. 297.
    Vargish T, Beamer KC, Daly T, Head R (1987) Myocardial opiate receptor activity is stereospecific, independent of muscarinic receptor antagonism, and may play a role in depressing myocardial function. Surgery 102: 171–177PubMedGoogle Scholar
  298. 298.
    De Castro J, Viars P, Leleu JCL (1969) Utilisation de la pentazocine comme analgésique pour le traitement des douleurs post-opératoires. Etude comparative entre le pethidine, la piritramide et la pentazocine. In: De Castro J (ed) Utilisation de la pentazocine en anesthésie et réanimation. Ars Medici, Bruxelles, pp 99–109Google Scholar
  299. 299.
    Michaels I, Trout JR, Barash PG (1984) Nitrous oxide as an adjunct to narcotic anesthesia. In: Estafanous FG (ed) Opioids in anesthesia. Butterworth, Boston London, pp 256–260Google Scholar
  300. 300.
    Michaels I, Barash PC (1983) Does nitrous oxide or a reduced FI02 alter the hemodynamic function during high dose sufentanil anesthesia? Anesth Analg 62: 275CrossRefGoogle Scholar
  301. 301.
    Freye E (1975) Effects of high doses of fentanyl on myocardial infarction and cardiogenic shock in the dog. Resuscitation 3: 105–113CrossRefGoogle Scholar
  302. 302.
    Hess L, Vrana M, Vranova Z, Fejfar Z (1989) The antifibril-latory effect of fentanyl, sufentanil, and carfentanil in the acute phase of local myocardial ischemia in the dog. Acta Cardiol 150: 303–31 1Google Scholar
  303. 303.
    Saini V, Carr DB, Hagestad EL, Lown B, Verreir L (1988) Antifibrillatory action of the narcotic agent fentanyl. Am Heart J 115: 508–514CrossRefGoogle Scholar
  304. 304.
    Freye E, Avril G, Härtung E (1981) Les effets anti-arrythmi-ques des opiacés. Comparaison avec un beta-bloqueur chez le chien. Cahiers d’Anesthésiol 29: 591–598Google Scholar
  305. 305.
    DeSilva RA, Verrier RL, Lown B (1978) Protective effect of the vagotonic action of morphine sulfate on ventricular vulnerability. Cardiovasc Res 12: 167–181CrossRefGoogle Scholar
  306. 306.
    Suwatakul K, Weis OF, Alloza JL, Kelvie W, Weintraub K, Lasagna L (1983) Analysis of narcotic analgesic usage in the treatment of postoperative pain. JAMA 250: 926–929CrossRefGoogle Scholar
  307. 307.
    Gerwig WH, Thompson CW, Blades P (1951) Pain control following upper abdominal operations. Arch Surg 62: 678–682CrossRefGoogle Scholar
  308. 308.
    Morris T, Tracey J (1977) Lignocaine: its effect on wound healing. Br J Surg 64: 902–903PubMedCrossRefGoogle Scholar
  309. 309.
    Dundee JW (1977) Problems associated with strong analgesics. In: Harcus AW, Smith R, Whittle B (eds) Pain. New perspectives in measurement and management. Churchill Livingstone, Edinburgh London New York, pp 57–62Google Scholar
  310. 310.
    Ferrari HA, Fuson RL, Dent SJ (1969) The relationship of the anaesthetic agent to postoperative analgesic requirements. South Med J 62: 1201–1203PubMedCrossRefGoogle Scholar
  311. 311.
    Bonica JJ (1983) Pain research and therapy: achievements of the past and challenges of the future. In: Bonica JJ, Lindblom U, Iggo A (eds) Advances in pain research and therapy, vol 5. Raven, New York, pp 1–36Google Scholar
  312. 312.
    Porter J, Hick H (1980) Addiction rate in patients treated with narcotics. N Engl J Med 302: 123–126PubMedGoogle Scholar
  313. 313.
    Taub A (1982) Opioid analgesics in the treatment of chronic intractable pain of non-neoplastic origin. In: Kitahata LM, Collins JG (eds) Narcotic analgesics in anesthesiology. Williams and Wilkins, Baltimore, pp 199–208Google Scholar
  314. 314.
    Portenoy RK, Foley KM (1986) Chronic use of opioid analgesics in non-malignant pain. Report of 38 cases. Pain 25: 171–186PubMedCrossRefGoogle Scholar
  315. 315.
    Donald I (1977) Pain-a patients view. In: Harcus AW, Smith AWR, Whittle B (eds) Pain. New perspectives in measurement and management. Churchill Livingstone, Edinburgh London New York, pp 1–4Google Scholar
  316. 316.
    Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14: 363–372CrossRefGoogle Scholar
  317. 317.
    rwin JM (1977) The effect of Doxapram on buprenor-phine induced respiratory depression. Act Anaesth Belg 2: 93–106Google Scholar
  318. 318.
    Steffen P, Engelke J, Kutter B, Seeling W (1996) Nichtinvasive perioperative Analgesie nach Allgemeinanästhesien. Kombination von Dihydrocodein ret. mit den Nichtopio-idanalgetika Diclofenac und Metamizol. Schmerz 10: S51Google Scholar
  319. 319.
    Krizanits-Weine F, Bichler I, Müller A, Pietsch K, Frank M (1996) Präemptive Analgesie mit retardiertem Dihydrocodein bei Patienten mit elektiven Kniearthroskopien. Schmerz 10: S54Google Scholar
  320. 320.
    Freye E (1986) Die Wirkeffekte von Opioiden werden durch Subpopulationen von Rezeptoren vermittelt–Theoretische Grundlagen und praktische Folgerungen. Schmerz Pain Douleur 1: 3–9Google Scholar
  321. 321.
    Freye E (1986) Klinische Indikationsbereiche der Opioid- Agonisten, Agonisten-Antagonisten und der reinen Antagonisten. Schmerz Pain Douleur 2: 44–54Google Scholar
  322. 322.
    Herz A (1981) Opiat-Partialantagonisten. In: Kubicki S, Neuhaus GA (Hrsg) Pentazocin im Spiegel der Erfahrungen. Springer, Berlin Heidelberg New York, pp 19–21Google Scholar
  323. 323.
    Abboud TK, Zhu J, Gangolly J et al. (1991) Transnasal butorphanol: a new method for pain relief in postcesarean section pain. Acta Anaesthesiol Scand 35: 14–18PubMedCrossRefGoogle Scholar
  324. 324.
    Wetchler BV, Alexander CD, Uhll MA (1992) Transnasal butorphanol tartrate for pain control following ambulatory surgery. Curr Ther Res 52 /4: 571–580CrossRefGoogle Scholar
  325. 325.
    Shyu WC, Pittmann KS, Robinson D, Barbhairya RH (1993) Multiple-dose phase I study of transnasal butorphanol. Clin Pharmacol Ther 54: 34–41PubMedCrossRefGoogle Scholar
  326. 326.
    Joyce III TH, Kubicek MF, Skjonsky BS, Jones MM (1993) Efficacy of transnasal butorphanol tartrate in postepi-siotomy pain: a model to assess analgesia. Clin Therap 15 /1: 160–167Google Scholar
  327. 327.
    Couch J, Diamond D, Elkind A et al. (1993) Evaluation of the efficacy and safety of Stadol NS (transnasal butorphanol) in the treatment of acute migraine in outpatients. 7th World Congress on Pain. ISAP, ParisGoogle Scholar
  328. 328.
    Diamond S, Freitag FG, Diamond ML, Urban G (1992) Transnasal butorphanol in the treatment of migraine headache pain. Headache Quat Curr Treat Res 3 /2: 164–171Google Scholar
  329. 329.
    Houde RW (1979) Analgesic effectiveness of the narcotic agonist-antagonists. Br J Clin Pharmacol 7: 297S-308 SGoogle Scholar
  330. 330.
    Freye E, Helle G (1988) Der Agonist-Antagonist Nalbuphin verlängert die gastro-coekale Transitzeit und induziert kurzfristig Schmerzen nach Neurolepanästhesie mit Fentanyl. Anästhesist 37: 440–445Google Scholar
  331. 331.
    Arend I, von Arnim B, Nijssen J, Scheele J, Flohe L (1978) Tramadol und Pentazocin im klinischen Doppelblind- Crossover Vergleich. Arzneimittelforsch/Drug Res 28 /1: 199–208Google Scholar
  332. 332.
    Wermeling DP, Foster TS, Farrington EA et al. (1986) Patient-controlled analgesia using butorphanol for postoperative pain control: an open label study. In: Rosow CE (ed) Butorphanol tartrate: Research advances in multiple clinical settings, vol 12. Karger, Basel, pp 31–39Google Scholar
  333. 333.
    Jordan C (1979) A comparison of the respiratory effects of meptazinol, pentazocine and morphine. Br J Anaesth 51: 497–501PubMedCrossRefGoogle Scholar
  334. 334.
    Watson GS, Edmond P (1977) Analgesics and urethral function. In: Harcus AW, Smith R, Whittle B (eds) Pain. New perspectives in measurement and management. Churchill Livingstone, Edinburgh London New York, pp 27–33Google Scholar
  335. 335.
    Saarne A (1969) Clinical evaluation of a new analgesic piritramide. Acta Anaesthesiol Scand 13: 11–19PubMedCrossRefGoogle Scholar
  336. 336.
    Hermans B, Gommeren W, De Potter WP, Leysen JE (1983) Interaction of peptides and morphine-like narcotic analgesics with specifically labeled ju-and 5-opiate receptor binding. Arch Int Pharmacodyn 263: 317–319PubMedGoogle Scholar
  337. 337.
    Martin WR (1981) Mini-Symposium II. Multiple opioid receptors. Life Sei 28: 1547–1554CrossRefGoogle Scholar
  338. 338.
    Keeri-Szanto M (1979) Drugs or drums: what relives postoperative pain? Pain 6: 217–230PubMedCrossRefGoogle Scholar
  339. 339.
    Tamsen A, Hartwig P, Fagerlund C, Dahlstrom B, Bondes-sun U (1982) Patient-controlled analgesia therapy: clinical experience. Acta Anaesthesiol Scand 74: 157–160CrossRefGoogle Scholar
  340. 340.
    Thomas DW, Owen H (1988) Patient-controlled analgesia-the need for caution. Anaesthesia 43: 770–772PubMedCrossRefGoogle Scholar
  341. 341.
    White PF (1987) Mishaps with patient-controlled analgesia. Anesthesiology 66: 81–83PubMedCrossRefGoogle Scholar
  342. 342.
    Parker RK, Holtmann B, White PF (1991) Patient-controlled analgesia. Does a concurrent opioid infusion improve pain mangement after surgery? JAMA 266 /14: 1947–1952PubMedCrossRefGoogle Scholar
  343. 343.
    Coyle N, Mauskopf A, Maggard J, Foley KM (1986) Continuous subcutaneous infusion of opiates in cancer pain patients. ONF 13 /4: 53–57Google Scholar
  344. 344.
    Lehmann KA (1984) Neue Möglichkeiten zur Behandlung akuter Schmerzen. Arzneimittelforsch/Drug Res 34: 1108–1114Google Scholar
  345. 345.
    Butscher K, Mazoit JY, Samii K (1995) Can immediate opioid requirements in the post-anaesthesia care unit be used to determine analgesic requirements on the ward? Can J Anaesth 42: 461–466PubMedCrossRefGoogle Scholar
  346. 346.
    Krimmer H, Pfeiffer H, Arbogast R, Sprotte G (1986) Die kombinierte Infusionsanalgesie–Ein alternatives Konzept zur postoperativen Schmerztherapie. Chirurg 57: 327–329PubMedGoogle Scholar
  347. 347.
    Foley KM (1986) Current controversies in opioid therapy. In: Foley FM, Inturisse CE (eds) Advances in pain research and therapy, vol 8. Raven, New York, pp 3–11Google Scholar
  348. 348.
    Nielsson Ml, Groenbladh L, Widerloev E, nggard E (1983) Pharmacokinetic of methadone maintenance treatment: Characterization of therapeutic failures. Eur J Clin Pharmacol 25: 497–501Google Scholar
  349. 349.
    Taeger K (1981) Pharmakokinetik der Opiate Dolantin, Morphin und Fentanyl. Anästh Intensivmed 2 /28Google Scholar
  350. 350.
    Wörz R, Berlin J (1989) Behandlung chronischer Schmerzsyndrome mit Antidepressiva. Schmerz 3: 1–7PubMedCrossRefGoogle Scholar
  351. 351.
    Tao P-L, Law P-Y, Loh HH (1986) Decrease in delta und mu opioid receptor binding capacity oin rat brain after chronic treatment. J Pharmacol Expt Ther 240: 809–816Google Scholar
  352. 352.
    Tao P-L, Chang L-R, Law PY, Loh HH (1988) Decrease in 5-opioid receptor density in rat brain after chronic (D-Ala2,D-Leu5) enkephalin treatment. Brain Res 462: 313–320PubMedCrossRefGoogle Scholar
  353. 353.
    Elliott TE, Elliott BA (1992) Physicians attitudes and beliefs about use of morphine for cancer pain. J Pain Sympt Manag 3 /7: 141–148CrossRefGoogle Scholar
  354. 354.
    Robbins LN, Davis DH, Nurco DM (1974) How permament was Vietnam drug addiction. Am J Public Health 64: 38–43CrossRefGoogle Scholar
  355. 355.
    Maruto T, Swanson DW, Finlayson RE (1979) Drug abuse and dependency in patients with chronic pain. Mayo Clin Proc 54: 241–244Google Scholar
  356. 356.
    Tennant FS, Kelman GF (1983) Narcotic maintenance for chronc pain: medical and legal guidelines. Postgrad Med 73: 81–94Google Scholar
  357. 357.
    Twycross RG, Lack SA (1983) Symptom control in far-advanced cancer. Pain relief. Pittman, LondonGoogle Scholar
  358. 358.
    Bohn LM, Jefkowitz RJ, Gainetdinov RG, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking ß-arrestin 2. Science 286: 2495–2498PubMedCrossRefGoogle Scholar
  359. 359.
    Kanner RM, Foley KM (1981) Pattern of narcotic drug use in cancer pain clinic. Ann NY Acad Sei 362: 162–172CrossRefGoogle Scholar
  360. 360.
    Smith GD, Smith MT (1995) Morphine-3-glucuronide: evidence to support the putative role in the development of tolerance to the antinociceptive effect in the rat. Pain 62: 51–60PubMedCrossRefGoogle Scholar
  361. 361.
    Morley JS, Watt JWG, Wells JC, Miles JB, Finnegan MJ, Leng G (1993) Methadone in pain uncontrolled by morphine. Lancet 342: 1243PubMedCrossRefGoogle Scholar
  362. 362.
    Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be K-opioid receptor mediated. Pain 73: 151–157PubMedCrossRefGoogle Scholar
  363. 363.
    Grabinski PY, Kaiko RF, Rogers AG, Houde RW (1983) Plasma levels and anlgesia following deltoid and gluteal injections of methadone and morphine. J Clin Pharmacol 23 /48Google Scholar
  364. 364.
    Rutter P, Muprphy F, Dudley H (1980) Controlled trial of different methods of administration of postoperative pain relief. BMJ 1: 3–12Google Scholar
  365. 365.
    Bruera E, Chadwick S, Bacovsky R (1981) Continuous subcutaneous infusion of narcotics using a portable disposable pump. J Palliat Care 1: 45–47Google Scholar
  366. 366.
    Waldmann C, Eason J, Rambohul E (1984) Serum morphine levels. A comparison between continuous subcutaneous and intravenous infusion in postoperative patients. Anaesthesia 39: 768–771Google Scholar
  367. 367.
    Dickson R, Russell P (1982) Continuous subcutaneous analgesia for terminal care at home. Lancet I: 165Google Scholar
  368. 368.
    Goeke H, Herbst M, Frucht U (1992) Schmerztherapeutische Tumornachsorge. Klinikarzt 1: 1–4Google Scholar
  369. 369.
    Goecke H, Herbst M (1993) Ambulante kontinuierliche subkutane Opioidanalgesie als PCAO (patient controlled analgesia in outpatients) bei schweren Tumorschmerzen. Schmerz 7: 31–39CrossRefGoogle Scholar
  370. 370.
    Duthie DJR, Rowbotham DJ, Wyld R, Henderson PD, Nimmo WS (1988) Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br J Anaesth 60: 614–618PubMedCrossRefGoogle Scholar
  371. 371.
    Plezia PM, Kramer TH, Linford J, Hameroff SR (1989) Transdermal fentanyl pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy 9: 2–9PubMedGoogle Scholar
  372. 372.
    Rowbotham DJ, Wyld R, Peacock JE, Duthie DJR, Nimmo WS (1989) Transdermal fentanyl for the relief of pain after upper abdominal surgery. Br J Anaesth 63: 56–59PubMedCrossRefGoogle Scholar
  373. 373.
    Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR (1989) Absorption characteristics of transdermal administered fentanyl. Anesthesiology 70: 928–934PubMedCrossRefGoogle Scholar
  374. 374.
    Larijani GE, Brell SD, Goldberg ME, Lessin JB (1988) Pharmacokinetics of fentanyl following transdermal application. Anesthesiology 69: A 363Google Scholar
  375. 375.
    Southam M, Gupta S, Knowles M, Hwang SS (1991) Transdermal fentanyl: an overview of pharmacokinetics, efficacy and safety. In: Lehmann KA, Zech D (eds) Transdermal fentanyl. Springer, Berlin Heidelberg New York, pp 107–116CrossRefGoogle Scholar
  376. 376.
    Hill HF (1990) Clinical pharmacology of transdermal fentanyl. Eur J Pain 11: 81–91Google Scholar
  377. 377.
    Payne R (1990) Experience with transdermal fentanyl in advanced cancer pain. Eur J Pain 11: 98–101Google Scholar
  378. 378.
    Nimmo WS (1990) Clinical summary: Transdermal fentanyl. Eur J Pain 11: 102–103Google Scholar
  379. 379.
    Duthie DJR, Nimmo WS (1987) Adverse effects of opioid analgesic drugs. Br J Aneasth 60: 61–77CrossRefGoogle Scholar
  380. 380.
    Hoiley PO, van Steenis C (1988) Postoperartive analgesia with fentanyl: pharmacokinetics and pharmakodynamics of constant rate iv and transdermal delivery. Br J Anaesth 60: 608–613CrossRefGoogle Scholar
  381. 381.
    Twycross RG (1984) Relief of pain. In: Saunders C (ed) The mangemement of terminal malignant disease. Edward Arnold, London, pp 64–90Google Scholar
  382. 382.
    Portenoy RK, Hagen NA (1990) Breakthrough pain: Definition, prevelance and characteristics. Pain 41: 273–281Google Scholar
  383. 383.
    Ahmedzai S, Brooks D (1997) Transdermal fentanyl vs. sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 13: 254–261PubMedCrossRefGoogle Scholar
  384. 384.
    Allen L, Hays H, Jensen NH et al. (1998) Evidence for better analgesia with transdermal fentanyl in chronic pain treatment. Comparison with sustained release morphine in a cross-over efficacy, safety and quality of life trial. Proceedings 10th European Congress of Anesthesiology. Springer, Frankfurt am MainGoogle Scholar
  385. 385.
    McLesky CH (1990) Fentanyl TTS for postoperative analgesia. Eur J Pain 11: 92–97Google Scholar
  386. 386.
    Haak R, Gupta S (1993) Pulsatile drug delivery from elec-trotransport therapeutic systems. In: Fumy R, Junginger H, Peppas N (eds) Pulsatile drug delivery. Current applica-tions and future trends. Wiss. Verlagsges., Stuttgart, pp 99–112Google Scholar
  387. 387.
    Maier C (1996) Ganglionäre lokale Opioidanalgesie (GLOA). Thieme, Stuttgart New YorkGoogle Scholar
  388. 388.
    Wulf H, Maier C, Scheie HA (1991) Die Behandlung von Zoster-Neuralgien. Anästhesist 40: 523–529Google Scholar
  389. 389.
    Stein C, Comisel K, Haimerl E et al. (1991) Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Eng J Med 325: 1123–1126CrossRefGoogle Scholar
  390. 390.
    Glynn CJ, Casale R (1993) Morphine injected around the stellate ganglion does not modulate the sympathetic nevous system nor does it provide pain relief. Pain 53: 33–38PubMedCrossRefGoogle Scholar
  391. 391.
    Laduron PH, Janssen FMH (1982) Axoplasmatic transport and possible recycling of opiate receptors labeled with 3H-lofentanil. Life Sei 31: 457–462CrossRefGoogle Scholar
  392. 392.
    Stein C, Millan MJ, Yassouridis A, Herz A (1988) Antinociceptive effects of jj-and k-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmacol 155: 255–264PubMedCrossRefGoogle Scholar
  393. 393.
    Stein C, Hassan A, Przewlocki R, Gramsch C, Peter K, Herz A (1990) Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Physiol Pharmacol 87: 5934–5939Google Scholar
  394. 394.
    Ashburn MA, Streisand JB (1994) Oral transmucosal fen-tanyl-help or hindrance? Drug Safety 11: 295–300PubMedCrossRefGoogle Scholar
  395. 395.
    Chien YW, Chang SF (1987) Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carr Syst 4: 67–194Google Scholar
  396. 396.
    Seymour D, Freitag FG, Diamond ML, Urban G (1992) Transnasal butorphanol in the treatment of migraine headache pain. Headache Quat Curr Treat Res 3: 164–171Google Scholar
  397. 397.
    Eagen KJ, Ready L (1994) Patient satisfaction with intravenous PCA or epidural morphine. Can J Anaesth 41: 6–11CrossRefGoogle Scholar
  398. 398.
    Striebel HW, Koenigs D, Krämer J (1992) Postoperative pain management by intranasal demand-adapted fen-tanyl titration. Anesthesiology 77: 281–285PubMedCrossRefGoogle Scholar
  399. 399.
    Abrams R, Morrison JE, Villasenor A, Hencmann D, Da Fon-seca M, Mueller W (1993) Saftey and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesth Prog 40: 63–66PubMedGoogle Scholar
  400. 400.
    Helmers JH, Noorduin H, van Peer A, Van Leuwen L, Zuurmond WW (1989) Comparison of intravenous and intranasal sufentanil adsorption and sedation. Can J Anaesth 36: 494–497PubMedCrossRefGoogle Scholar
  401. 401.
    Striebel WH, Malewicz J, Hermanns K (1993) Intranasal meperidine titration for postoperative pain relief. Anesth Analg 76: 1047–1051PubMedCrossRefGoogle Scholar
  402. 402.
    Oral U, Isik G, Özbek H, Güler T (1995) Intranasal alfentanil for postoperative pain relief. BrJ Anaesth 74: 139Google Scholar
  403. 403.
    Schwagmeier R, Boerger N, Meissner W, Striebel HW (1995) Pharmacokinetics of intranasal alfentanil. J Clin Anesth 7: 109–113PubMedCrossRefGoogle Scholar
  404. 404.
    Striebel WH, Wessel A, Rieger A (1993) Intranasales Fentanyl zur Therapie akuter Schmerzspitzen bei Karzinompatienten. Eine Pilotstudie. Schmerz 7: 174–178Google Scholar
  405. 405.
    Striebel HW, Olmann T, Spies C, Brummer G (1996) Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. J Clin Anaesth 8: 4–8CrossRefGoogle Scholar
  406. 406.
    Farncombe M, Chater S (1994) Clinical application of nebulized opioids for treatment of dyspnoe in patients with malignant disease. Sup Care Cancer 2: 184–187CrossRefGoogle Scholar
  407. 407.
    Masters N, Heap G, Wedley MJ, Moore A (1988) Inhaled nebulized morphine and diamorphine: useful in general practice? Practitioner 232: 910–914PubMedGoogle Scholar
  408. 408.
    Chrubasik J, Wüst H, Friedrich G, Geller E (1988) Absorption and bioavailability of nebulized morphine. Br J Anaesth 61: 228–230PubMedCrossRefGoogle Scholar
  409. 409.
    Otulana BA, Morishige RJ, Beckman RA et al. (1999) Oral inhalation system for delivery of morphine produces an iv-like profile. In: 9th World Congress on Pain. IASP Press, Vienna, p 337Google Scholar
  410. 410.
    Stanley TH, de Lange S (1988) Comparison of sufentanil-oxygen and fentanyl-oxygen anesthesia for mitral and aortic valvular surgery. J Cardiothoracic Anesth 2: 6–11CrossRefGoogle Scholar
  411. 411.
    Sebel PS, Bovill JG, Wauquier A, Rog P (1981) Effects of high dose fentanyl anesthesia on the electroencephalogram. Anesthesiology 55: 203–211PubMedCrossRefGoogle Scholar
  412. 412.
    Bovill JG, Sebel PS, Wauquire A, Rog P, Schuytt HC (1983) Influence of high-dose alfentanil in anesthesia on the electroencephalogram: Correlation with plasma concentrations. Br J Anaesth 55: 199S - 209SPubMedGoogle Scholar
  413. 413.
    Tolksdorf W, Schäfer E, Pfeiffer J, von Mittelstaedt G (1987) Adrenalin-, Noradrenalin-, Blutdruck-und Herz-freqenzverhalten während der Intubation in Abhängigkeit unterschiedlicher Fentanyl-Dosen. Anästh Intensivther Notfallmed 22: 171–176Google Scholar
  414. 414.
    Podiesch I (1988) Disoprivan (Propofol)-ein neues intravenöses Hypnotikum. Fortschr Anaesth 2: 1–31Google Scholar
  415. 415.
    Cockshott ID (1985) Propofol (Diprivan) pharmacokinetics and metabolism–an overview. Postgrad Med J 61: 45–50PubMedGoogle Scholar
  416. 416.
    Härtung E, Freye E (1988) An open comparison of propofol and enflurane for prolonged abdominal operations. Anaesthesia 43: 105–107PubMedCrossRefGoogle Scholar
  417. 417.
    Grant IS, MacKenzie N (1985) Recovery following propofol ( Diprivan) anaesthesia - a review of three different anaesthetic techniques. Postgrad Med J 61: 133–137Google Scholar
  418. 418.
    Stark RD, Binks SM, Dutka VN, O’Connor KM, Armstein MJA, Glen JB (1985) A review of the safety and tolerance of propofol ( Diprivan ). Postgrad Med J 61: 152–156Google Scholar
  419. 419.
    Nauta J, de Lange S, Koopman D, Speidijk J, van Kleef J, Stanley T (1982) Anesthetic induction with alfentanil: A new short-acting narcotic analgesic. Anesth Analg 61: 267–272Google Scholar
  420. 420.
    Freye E, Härtung E (1988) Der spezifische Antagonist »Flumazenil« bei Benzodiazepin-lntoxikationen. Dtsch Ärztebl 42: 2909–2914Google Scholar
  421. 421.
    Freye E, Neruda B, Falke K (1989) Flumazenil ( Anexate) for the reversal of residual benzodiazepine activity. Drugs Today 25: 119–124Google Scholar
  422. 422.
    Bergmann SA, Wynn RL, Peterson MD, Rudo FG (1988) GABA agonists enhance morphine and fentanyl antinoci-ception in rabbit tooth pulp and mouse hot plate test. Drug Dev Res 14: 111–122CrossRefGoogle Scholar
  423. 423.
    Tejwani GA, Rattan AK, Sribanditmongkol P, Sheu M-J, Zuniga J, McDonald JS (1993) Inhibition of morphine-induced tolerance and dependence by a benzodiazepine receptor agonist midazolam in the rat. Anesth Analg 76: 1052–1060PubMedCrossRefGoogle Scholar
  424. 424.
    Rosland JH, Kole K (1990) 1,4-Benzodiazepines antagonize opiate-induced antinociception in mice. Anesth Analg 71: 242–248Google Scholar
  425. 425.
    Rosland JH, Hunskaar S, Hole K (1990) Diazepam attenuates morphine antinociception test-dependently in mice. Pharmacol Toxicol 66: 382–386PubMedCrossRefGoogle Scholar
  426. 426.
    Luger TJ, Hill HF, Hayashi T, Zech C, Yaksh TL (1993) Spinal potentiating and supraspinal inhibitory effect of midazolam on morphine analgesia in rats. In: Proceedings 7th World Congress on Pain. IASP Publ, Paris, pp 201–202Google Scholar
  427. 427.
    McLesky CH (1984) Comparison of three infusion rates of alfentanil and incremental fentanyl as adjunct to nitrous oxide anesthesia for general surgery. Janssen Clin Res RepGoogle Scholar
  428. 428.
    Stanley TH (1982) Comparison of alfentanil with thiopental sodium for induction of anesthesia. Janssen Pharma-zeutika, Beerse/BelgiumGoogle Scholar
  429. 429.
    Murphy MR, Hug CC (1982) The anesthetic potency of fentanyl in terms of its reduction of enflurane MAC. Anesthesiology 57: 485–488PubMedCrossRefGoogle Scholar
  430. 430.
    Ismaily AJ, Mötsch J, Altmayer P, Bleser W, Hutschenreuter K (1987) Die Auswirkungen einer Kombinationsanästhesie mit Fentanyl und Enfluran auf den Kreislauf und die unmittelbare postoperative Phase. Anäst Intensivmed 28: 216–220Google Scholar
  431. 431.
    Härtung HJ (1988) Klinische Erfahrungen mit Alfentanil zur »balanced anesthesia« bei Oberbauch-Eingriffen. Anästhesist 37: 620–624Google Scholar
  432. 432.
    Skubella U, Hucke H (1989) Alfentanil-Kombinationsnar-kose bei der Adeno-Tonsillektomie im Kindesalter–ein Vergleich mit der Enfluran-Inhalationsanästhesie. Anästh Intensivther Notfallmed 24: 362–367PubMedCrossRefGoogle Scholar
  433. 433.
    Brizgys RV, Morales R, Owens B (1985) Effects of thiopental requirements and hemodynamic response during induction and intubation. Anesthesiology 63: A377CrossRefGoogle Scholar
  434. 434.
    Smith NT, Westover CJ, Qinn M, Benthuysen L, Silver DH, Sanford TJ (1985) An electroencephalographic comparison of alfentanil with other narcotics and with thiopental. J Clin Monit 1: 236–244PubMedCrossRefGoogle Scholar
  435. 435.
    Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D (1995) The epidural Clonidine study group. Epidural Clonidine analgesia for intractable cancer pain. Pain 61: 391–399Google Scholar
  436. 436.
    Aantaa R, Kanto J, Scheinin M, Kallio A, Scheinin H (1990) Dexmedetomidine, an alpha 2-adrenoreceptor agonist, reduces anesthetic requirements for patients under going minor gynecologic surgery. Anesthesiology 73: 230–235PubMedCrossRefGoogle Scholar
  437. 437.
    Flacke JW, Bloor BC, Flacke WE et al. (1987) Reduced narcotic requirement by Clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology 67: 11–19PubMedCrossRefGoogle Scholar
  438. 438.
    Engelman E, Lipzyc M, Gilbert E et al. (1989) Effects of Clonidine on anesthetic requirements and hemodynamic response during aortic surgery. Anesthesiology 71: 178–187PubMedCrossRefGoogle Scholar
  439. 439.
    Noyer M, De Laveleye F, Vauquelin G, Gobert J, Wülfert E (1994) Mivazerol, a novel compound with high binding specificity for alpha2 adrenergic receptor: Binding studies on different human and rat membrane preparations. Neu-rochem Int 24: 221–229Google Scholar
  440. 440.
    McSPI-Europe (1997) Perioperative sympathicolysis. Beneficial effects of the alpha2-agonist mivazerol on hemodynamic stability and myocardial ischemia. Anesthesiology 86: 346–363CrossRefGoogle Scholar
  441. 441.
    Hoffmann WE, Kochs E, Werner C, Thomas C, A. RF (1991) Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat: reversal by the alpha2 antagonist atipamezole. Anesthesiology 75: 328–332CrossRefGoogle Scholar
  442. 442.
    Mötsch J, Gräber E, Ludwig K (1990) Addition of Clonidine enhances postoperative analgesia from epidural morphine a double blind study. Anesthesiology 73: 1067–1073PubMedCrossRefGoogle Scholar
  443. 443.
    Carabine UA, Milligan KR, Moore J (1992) Extradural Clonidine and bupivacaine for postoperative analgesia. Br J Anaesth 68 /2: 132–135PubMedCrossRefGoogle Scholar
  444. 444.
    Maze M, Tranquilli W (1991) Alpha-2 adrenoreceptor agonists: Defining the role in clinical anesthesisa. Anesthesiology 74: 581–605Google Scholar
  445. 445.
    Striebel HW, Koenigs D, Heil T (1993) Clonidin-Stellenwert in der Anästhesie. Anästhesist 42: 131–141Google Scholar
  446. 446.
    Blum K (1980) Alcohol and opiates. A review of common mechanism. In: Lacasse L, Levy M, Manzo L (eds) Neuro-toxikology. Pergamon, Oxford, pp 71–90Google Scholar
  447. 447.
    Haber H, Melzig M (1992) Tetrahydroisoqinoline-endo-gene Produkte nach chronischem Alkoholabusus. Pharmazie 47: 3–7PubMedGoogle Scholar
  448. 448.
    Cohen G (1979) Interaction of catecholamines with acetal-dehyde to form tetrahydroisoquinoline neurotransmitters. In: Sharp CW, Abood L (eds) Membrane Mechanisms of drugs of abuse. Progr Clin Biol Res 27: 73–90Google Scholar
  449. 449.
    Melchior CL, Collins MA (1982) The route and significance of endogenous synthesis of alkaloids in animals. Crit Rev Tox 9: 313–356CrossRefGoogle Scholar
  450. 450.
    Collins MA (1980) Neuroamine condensation in human subjects. In: Begleiter H (ed) Biological effects of alcohol. Plenum Press, New York, pp 87–102Google Scholar
  451. 451.
    Hoffman PL, Urwyler S, Tabakoff B (1982) Alterations in opiate receptor function after chronic ethanol exposure. J Pharmacol Exp Ther 222: 182–189PubMedGoogle Scholar
  452. 452.
    Herz A (1980) Pharmacological modulation of opiate-like peptide systems. Pharmacol Biochem Behav 1 (Suppl): 165–268Google Scholar
  453. 453.
    Schulz R, Wüster M, Duka T, Herz A (1980) Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary. Psychopharmacology 68: 221–227PubMedCrossRefGoogle Scholar
  454. 454.
    Hug CCJ (1984) Pharmacokinetics of new synthetic narcotic analgesics. In: Estafanous FG (ed) Opioids in anesthesia. Butterworth, Boston, pp 50–60Google Scholar
  455. 455.
    McDonnell TE, Bartowski RR, Williams JJ (1982) ED50 of alfentanil for induction of anesthesia in unpremedicated young adults. Anesthesiology 57: A 362Google Scholar
  456. 456.
    Stanski DR, Hug CC (1982) Alfentanil-a kinetically predictable narcotic analgesic. Anesthesiology 57: 435–438PubMedCrossRefGoogle Scholar
  457. 457.
    Suttmann H, Doenicke A (1983) Interim report on dose-establishment with alfentanil. Janssen Pharmaceutica, Beerse/BelgiumGoogle Scholar
  458. 458.
    Freye E, Härtung E, Buhl R (1986) Alfentanil als letzte Dosis (on-top) in der Neuroleptanalgesie mit Fentanyl. Anästhesist 35: 231–237Google Scholar
  459. 459.
    Shafer SL, Varvel JR (1991) Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 74 /1: 53–63PubMedCrossRefGoogle Scholar
  460. 460.
    Chapmann CR, Colpitts YM, Benedetti C, Butler S (1982) Event-related potential correlates of analgesia comparison of fentanyl, acupuncture and nitrous oxide. Pain 14: 327–337CrossRefGoogle Scholar
  461. 461.
    Freye E, Härtung E, Schenk GK (1989) Somatosensory-evoked potentials during block of surgical stimulation with propofol. Br J Anaesth 63: 357–359PubMedCrossRefGoogle Scholar
  462. 462.
    Kochs E, Treede RD, Schulte am Esch J, Bromm B (1990) Modulation of pain-related somatosensory evoked potentials by general anesthesia. Anesth Analg 71: 225–2230PubMedCrossRefGoogle Scholar
  463. 463.
    Freye E (1985) Somatosensorisch evozierte Potentiale (SEP) zur Algesiemetrie. In: Zindler M, Härtung E (eds) Alfentanil-Ein neues, ultrakurzwirkendes Opioid. Urban and Schwarzenberg, München Wien Baltimore, pp 17–23Google Scholar
  464. 464.
    Freye E (1991) Opiate und Opiatantagonisten. II. Der praktische Einsatz der Opioide. DAZ 49: 2605–2615Google Scholar
  465. 465.
    Egan TD (1995) Remifentanil pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 29: 80–94PubMedCrossRefGoogle Scholar
  466. 466.
    Hermann DJ, Marton JP, Donn KH et al. (1991) Pharmacokinetic comparison of GI87084B, a novel ultra-short acting opioid, and alfentanil. Anesthesiology 75: A 379Google Scholar
  467. 467.
    Flacke JW, Bloor BC, Kripke BJ, Flacke WE, Warneck CM (1985) Comparison of meperidine, fentanyl and sufentanil in balanced anesthesia. Anesth Analg 64: 897–910PubMedGoogle Scholar
  468. 468.
    De Lange S, Boscoe MJ, Stanley TH, De Bruijn N, Philbin DM, Coggins CH (1982) Antidiuretic and growth hormone responses during coronary artery surgery with sufentanil-oxygen and alfentanil-oxygen anesthesia in man. Anesth Analg 61: 434PubMedCrossRefGoogle Scholar
  469. 469.
    De Lange S, Stanley TH, Boscoe MJ et al. (1983) Catecholamine and Cortisol responses to sufentanil-02 and alfentanil-02 anaesthesia during coronary artery surgery. Can Anaesth Soc J 30: 248–255PubMedCrossRefGoogle Scholar
  470. 470.
    Bailey PL, Streisand JB, Pace NL, Bayless J, Stanley TH (1986) Sufentanil produces shorter lasting respiratory depression and longer lasting analgesia than equipotent doses of fentanyl in human volunteers. Anesthesiology 65: A 493Google Scholar
  471. 471.
    Freye E (1991) Opioide–Zentrale Analgetika. Ihre Wirkweise beim Menschen. DIA-GM 12: 1105–1118Google Scholar
  472. 472.
    Bowdle TA, Ward RJ (1989) Induction of anesthesia with small doses of sufentanil or fentanyl: Dose vs. EEG response, speed of onset, and thiopental requirement. Anesthesiology 70: 26–30Google Scholar
  473. 473.
    Brian SE, Seifen AB. Tonic-clonic activity after sufentanil. Anesth Analg 1987 66: 481PubMedCrossRefGoogle Scholar
  474. 474.
    Katz Rl, Eide TR, Hartman A, Poppers PJ (1988) Two instances of seizure-like activity in the same patient associated with two different narcotics. Anesth Analg 67: 289PubMedGoogle Scholar
  475. 475.
    Young WL, Prohovnik I, Carrell JW, Ornstein E (1988) The effect of sufentanil on cerebral hemodyamics during carotid endarterectomy. Anesthesiology 69: A 591Google Scholar
  476. 476.
    Keykhah MM, Smith DS, Carlson C (1985) Influence of sufentanil on cerebral metabolism and circulation in the rat. Anesthesiology 63: 274–277PubMedCrossRefGoogle Scholar
  477. 477.
    Werner C (1992) Der Einfluß von Sufentanil auf die regionale und globale Hirndurchblutung und den zerebralen Sauerstoffverbrauch beim Hund. Anästhesist 41: 34–38Google Scholar
  478. 478.
    Milde LN, Milde JH, Gallagiter WJ (1990) Effects of sufentanil on cerebral circulation and metabolism in dogs. Anesth Analg 70 /2: 138–146PubMedCrossRefGoogle Scholar
  479. 479.
    Weinstabl C, Mayer N, Richling B, Czech T, Spiss CK (1991) Effects of sufentanil on intracranial pressure in neurological patients. Anaesthesia 46: 837–840PubMedCrossRefGoogle Scholar
  480. 480.
    Sperry RJ, Bailey PL, Reichman MV, Peterson JC, Peterson PB, Pace NL (1992) Fentanyl und sufentanil increase intracranial pressure in head trauma patients. Anesthesiology 77 /3: 416–420PubMedCrossRefGoogle Scholar
  481. 481.
    Stephan H, Gröger P, Weyland A, Hoeft A, Sonntag H (1991) Einfluß von Sufentanil auf Hirndurchblutung, Hirnstoffwechsel und die C02-Reaktivität der menschlichen Hirngefäße. Anästhesist 40: 153–160Google Scholar
  482. 482.
    Mathews HML, Furness G, Carson IW (1988) Comparison of sufentanil-oxygen and fentanyl-oxygen anaestheia for coronary artery bypass grafting. B J Anaesth 60: 530–535CrossRefGoogle Scholar
  483. 483.
    Hecker BR, Lake CL, DiFazio CA, Moscicki JC, Engle JS. The decrease of the minimum alveolar anesthetic concentration produced by sufentanil in rats. Anesth Analg 1983 62: 987–990PubMedCrossRefGoogle Scholar
  484. 484.
    Hall Rl, Murphy MR, Hug CC (1987) The enflurane sparing effect of sufentanil in dogs. Anesthesiology 67: 518–525PubMedCrossRefGoogle Scholar
  485. 485.
    Gravlee GP, Ramsey FM, Roy RC (1987) Rapid administration of a narcotic and a neuromuscular blocker: A hemodynamic comparison of fentanyl, sufentanil, pancuronium, and vecuronium. Anesth Analg 67: 39–47Google Scholar
  486. 486.
    Freye E (1994) Opioide und NSAIDs. In: Doenicke A (Hrsg) Zentraleuropäischer Anästhesiekongress, Wien. Anästhesist 44/2: S149Google Scholar
  487. 487.
    Helmers JH, Van Leuwen L, Zuurmond W (1989) Sufen-tanil-Dosierungsstudie bei allgemeinen chrirurgischen Eingriffen. Anästhesist 38: 397–400Google Scholar
  488. 488.
    Monk JP, Beresford R, Ward A (1988) Sufentanil. A review of its pharmacological properties and therapeutic use. Drugs 36: 286–313Google Scholar
  489. 489.
    Morton JP, Hardman HD, Kamiyama Y, Donn KH, Glass PSA (1991) Analgesic efficacy of single escalating doses of Gl 87084B administered intravenously to healthy adult male volunteers. Anesthesiology 75/3 A: A378Google Scholar
  490. 490.
    Schuster SV, Bilotta JM, Lutz MW, James MK (1991) Analgesic activity of the ultrashort acting opioid, Gl 87804B. FASEB Journal 5 /4: 2846Google Scholar
  491. 491.
    Westmoreland C, Sebel PS, Hug Jr CC, Hoke JF, Muir KT (1993) Histamine levels and hemodynamic responses following remifentanil. Anesthesiology 79 /3: A111Google Scholar
  492. 492.
    Westmoreland C, Hoke JF, Sebel PS, Hug Jr CC, Muir LT (1993) Pharmacokinetics of remifentanil (GI87084B). Anesthesiology 79 /3: A372Google Scholar
  493. 493.
    Egan TD, Lemmens HJM, Fiset P et al. (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 79: 881–892PubMedCrossRefGoogle Scholar
  494. 494.
    Anand KJS, Brown MJ, Canson RC, Christofides ND, Bloom SR, Aynsley-Green A (1985) Can the human neonate mount an endocrine and metabolic response to surgery? J Pediatr Surg 20: 41–48PubMedCrossRefGoogle Scholar
  495. 495.
    Anand KJS, Hansen DD, Hickey RP (1990) Hormonal-meta-bolic stress response in neonates undergoing cardiac surgery. Anesthesiology 73: 661–670PubMedCrossRefGoogle Scholar
  496. 496.
    Kanwal JS, Anand MB (1986) The stress response to surgical trauma: From physiological basis to therapeutic implications. Prog Food Nutr Sei 10: 67–123Google Scholar
  497. 497.
    Hickey PR, Hansen DD, Wessel DT, Lang P, Jonas RA (1985) Pulmonary and systemic hemodynamic responses to fentanyl in infants. Anesth Analg 64: 483–486PubMedGoogle Scholar
  498. 498.
    Anand KJS, Sippe WG, Aynsley-Green A (1987) Randomised trial of fentanyl anaesthesia in preterm babies undergoing surgery: effects on the stress response. Lancet I: 243–248Google Scholar
  499. 499.
    Anand KJS (1995) Analgesia and sedation in ventilated neonates. Neon Resp Dis 5: 1–10Google Scholar
  500. 500.
    Pinto-Martin JA, Riolo S, Cnaan A, Holzman C, Süsser MW, Paneth N (1995) Cranial ultrasound prediction of disabling and nondisabling cerebral palsy at age two in a low birth weight population. Pediatrics 95: 249–254PubMedGoogle Scholar
  501. 501.
    Low JA, Froese AB, Smith JT, Galbraith RS, Sauerbrei EE, Karchmar EJ (1992) Hypotension and hypoxemia in the preterm newborn during the four days following delivery identifies infants at risk of echosonographically demonstrable cerebral lesions. Clin Invest Med 15: 60–65PubMedGoogle Scholar
  502. 502.
    Anand KJS (1993) Relationships between stress responses and clinical outcome in newborns, infants, and children. Crit Care Med 21: S358 - S359PubMedCrossRefGoogle Scholar
  503. 503.
    Roizen MF, Lampe GH, Benefiel DJ (1987) Is increased operative stress associated with worse outcome? Anesthesiology 67: A1CrossRefGoogle Scholar
  504. 504.
    Fitzgerald M (1987) Neurobiology of fetal and neonatal pain. In: Wall PD, Melzack R (eds) The textbook of pain. Chirchill Livingstone, Edinburgh, pp 153–163Google Scholar
  505. 505.
    McGrath PJ, Johnson G, Goodman JT, Schillinger J, Dunn J, Chapmanm JA (1985) CHEOPS: A behavioral scale for rating postoperative pain in children. Adv Pain Res Ther 9: 395–402Google Scholar
  506. 506.
    Anand KJS, Craig D (1966) New perspectives on the definition of pain. Pain 67: 3–6Google Scholar
  507. 507.
    Taddio A, Goldbach M, Ipp M, Stevens B, Koren G (1995) Effect of neonatal circumcision on pain responses during vaccination of boys. Lancet 345: 291–292PubMedCrossRefGoogle Scholar
  508. 508.
    Johnston CC, Stevens B, Craig KD, Grunau RVE (1993) Developmental changes in pain expression in preterm, full-term, two-and four-month-old children. Pain 52: 201–208PubMedCrossRefGoogle Scholar
  509. 509.
    Reynold ML, Fitzgerald M (1995) Long-term sensory hyperinnervation following neonatal skin wounds. J Comp Neurol 9: 89–95Google Scholar
  510. 510.
    Fitzgerald M, Anand KJS. Developmental neuroanatomy and neurophysiology of pain. In: Schechter NL, Berde CB, Yasrter M (eds) (1994) Pain in infants, children and adolescents. Williams and Wilkins, Baltimore, pp 11–31Google Scholar
  511. 511.
    Grunau VE, Whitfield MF, Petrie JH (1994) Pain sensitivity and treatment in extremely low-birth-weight premature toddlers and pre-term and full-term controls. Pain 58: 341–346PubMedCrossRefGoogle Scholar
  512. 512.
    McGrath PA (1990) Pain in children: Nature, asssessment and management. Guilford, New YorkGoogle Scholar
  513. 513.
    Caspi A, Henry B, McGee RO, Moffitt TE, Silva PA (1995) Temperamental origins of child and adolescent behavior problems: from age three to age fifteen. Child Develop 66: 55–68PubMedCrossRefGoogle Scholar
  514. 514.
    Grunau RVE, Whitfield MF, Petrie JH, Fryer EL (1994) Early pain experience, child and family factors as precursors of somatization: a prospective study of extremely premature and fullterm children. Pain 56: 353–359PubMedCrossRefGoogle Scholar
  515. 515.
    Plotsky PM, Meaney MJ (1993) Early postnatal experience alters hypothalamic corticotropin-releasing factor ( CRF), mRNA, median eminence CRF content and stress-induced release in adult rats. Mol Brain Res 18: 195–200Google Scholar
  516. 516.
    Landfield PW, McEwan BS, Sapolsky RM, Meaney MJ (1996) Hippocampal cell death. Science 272: 1249–1251PubMedCrossRefGoogle Scholar
  517. 517.
    Anand KJS, McGrath PJ. Future directions. In: Anand KJS, McGrath PJ (eds) (1993) Pain in neonates. Elsevier, Amsterdam, pp 321–333Google Scholar
  518. 518.
    Meaney MJ, Sharma S, Sarrieau S, Plotsky PM (1988) Postnatal development and environmental regulation of hippocampal glucocorticoid and mineralocoticoid receptors in the rat. Dev Brain Res 43: 158–162CrossRefGoogle Scholar
  519. 519.
    McEwen BS (1994) The plasticity of the hippocampus is the reason for its vulnerability. Neurosciences 6: 239–246Google Scholar
  520. 520.
    Jacobson B, Eklund G, Hamberger L, Linnarsson D, Sevdall G, Vlaverius M (1987) Perinatal origin of adult self-destructive behavior. Acta Psychiat Scand 76: 364–371PubMedCrossRefGoogle Scholar
  521. 521.
    Schade JP, Ford H (1972) Basic Neurology, 2nd Edn. Elsevier, AmsterdamGoogle Scholar
  522. 522.
    Bauer-Miettingen U (1984) Probleme der postoperativen Schmerzbekämpfung bei Kindern. Orthopädie 13: 244–248Google Scholar
  523. 523.
    Williamson PS, Williamson ML (1983) Physiologie stress reduction by a local anesthetic during newborn circumcision. J Pediatr 71: 36–40Google Scholar
  524. 524.
    Coyle JT, Pert CB (1976) Ontogenetic development of (3H)-naloxone binding in rat brain. Neuropharmacology 15: 555–560PubMedCrossRefGoogle Scholar
  525. 525.
    Jacobsen M (1970) Developmental neurobiology. Holt, Rinehard and Winston, New YorkGoogle Scholar
  526. 526.
    Zhang AZ, Pasternak GW (1981) Ontogeny of opioid pharmacology and receptors: high and low affinity site differences. Eur J Pharmacol 73: 2940CrossRefGoogle Scholar
  527. 527.
    Purcell-Jones G, Dormon F, Sumner E (1987) The use of opioids in neonates. A retrospective study of 933 cases. Anaesthesia 42: 1320–1323CrossRefGoogle Scholar
  528. 528.
    Woltmann M, Roth BL, Coscia CJ (1982) Differential postnatal development of mu and delta opiate receptores. Dev Brain Res 3: 679–684CrossRefGoogle Scholar
  529. 529.
    Rosenbaum JS, Holford NHG, Sadee W (1985) In vivo receptor binding of opioid drugs at the mu site. J Pharmacol Exp Ther 233: 735–740PubMedGoogle Scholar
  530. 530.
    Holaday JW, Porreca F, Rothmann RB (1990) Functional coupling among opioid receptor types. In: Estafanous FG (ed) Opioids in anesthesia, vol II. Butterworth-Heine-mann, Boston London, pp 50–71Google Scholar
  531. 531.
    Goldmann A, Lloyd-Thomas AR (1991) Pain management in children. Br Med Bull 47: 676–689Google Scholar
  532. 532.
    Leslie FM, Tso S, Harlbutt DE (1982) Differential appearance of opiate receptor subtypes in neonatal rat brain. Life Sei 31: 1393–1396CrossRefGoogle Scholar
  533. 533.
    Gal TJ, Di Fazo CA, Moscicki J (1982) Analgesic and respiratory depressant activity of nalbuphine: a comparison with morphine. Anesthesiolog 57: 367–374CrossRefGoogle Scholar
  534. 534.
    Navarro G, Garcia-Flores S (1984) The use of nalbuphine vs. pethidine in women with labour pain. Mex J Gyn Obstet 5: 20–25Google Scholar
  535. 535.
    Pasternak GW, Zhang A, Tecott L (1980) Developmential differences between high and low affinity opiate binding sites: their relationship to analgesia and respiratory depression. Life Sei 27: 1185–1190CrossRefGoogle Scholar
  536. 536.
    Sircar R, Zukin SR (1983) Ontogenety of sigma opiate/ phencyclidine-binding sites in rat brain. Life Sei 33: 255–258CrossRefGoogle Scholar
  537. 537.
    Smith DJ, Bouchal RL, DeSanctis CA (1987) Properties of the interaction between ket amine and opiate binding sites in vivo and in vitro. Neuropharmacology 26: 1253–1260PubMedCrossRefGoogle Scholar
  538. 538.
    Freye E, Dähn H, Engel M (1989) Die zentralnervösen exzi-tatorischen Effekte von Ketamin werden durch den Zusatz von Midazolam verringert–Eine postnarkotische Untersuchung bei Patienten nach kieferchirurgischen Eingriffen in Spontanatmung. Anästh Intensivther Notfallmed 6: 368–372Google Scholar
  539. 539.
    Piepenbrock S (1987) Prinzipien der Schmerzbehandlung bei Kindern in der peri operativen Phase. In: Meier H (Hrsg) Analgesie bei Kindern. Perimed, Erlangen, pp 59–66Google Scholar
  540. 540.
    Ikkola KT, Hamunen K, Maunuksela EL (1995) Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 28: 385–404CrossRefGoogle Scholar
  541. 541.
    Roth B, Houben F, Hartwig S, Theisohn M, Schlünder C (1991) Erfahrungen zur Analgesie und Sedierung in der pädiatrischen Intensivmedizin. In: Henschel WF (Hrsg) I. Europäisches Analgesieforum–Die Analgesie im Mittelpunkt der Anästhesie. Urban and Schwarzenberg, München, Wien, Baltimore, pp 235–247Google Scholar
  542. 542.
    Greeley WJ, de Bruijn NP, Davis DP (1986) Pharmacokinetics of sufentanil in pediatric patients. Anesthesiology 65: A 422Google Scholar
  543. 543.
    Akil H, Watson SJ, Young E (1984) Endogenous opioids. Biology and function. Ann Rev Neurosci 7: 223–255Google Scholar
  544. 544.
    Greeley WJ, de Bruijn NP, Davis DP (1987) Sufentanil pharmacokinetics in pediatric cardiovascular patients. Anesth Analg 66: 1067–1072PubMedCrossRefGoogle Scholar
  545. 545.
    Cube von B, Teschemacher HJ, Herz A, Hess R (1970) Permeation morphinartiger Substanzen an den Ort der antinociceptiven Wirkung im Gehirn in Abhängigkeit von ihrer Lipoidlöslichkeit nach intravenöser und nach intraventrikulärer Applikation. Naunyn-Schmiedebergs Arch Pharmacol 265: 455–473CrossRefGoogle Scholar
  546. 546.
    Taeger K, Weninger E, Franke N, Finsterer U, Peter K (1984) Uptake of fentanyl by human lung. Anesthesiology 61: A246CrossRefGoogle Scholar
  547. 547.
    Scott JG, Cooke JE, Stanski DR (1991) Electroencephalo-graphic quantitation of opioid effects: Comparative phar-macodnamics of fentanyl and sufentanil. Anesthesiology 74: 34–42Google Scholar
  548. 548.
    Freye E (1989) Opioid agonists, antagonists and mixed narcotic analgesics: Their use in postoperative and chronic pain management. Drugs Today 25: 741–754Google Scholar
  549. 549.
    Okum G, Hauser A, Horrow J, Keykhah M, Begen S (1993) Sufentanil pharmaco kinetics during tourniquet use. Anesth Analg 76: S309Google Scholar
  550. 550.
    Schenk HD, Ensink FBM, Rhönisch M (1993) Alfentanil - Porträt eines Opioids zur Anästhesie. Urban and Schwarzenberg, München Wien BaltimoreGoogle Scholar
  551. 551.
    Sifton DW (1988) Drug Interaction and Side Effects Index™ 42 Edn. Physicians Desk Reference (PDR) Medical Economics Company, Oradell/N.Y.Google Scholar
  552. 552.
    Leak JA (1999) Herbal medicine: Is it an alternative or an unknown? A brief review of popular herbals used iby patients in a pain and symptom managmement practice setting. Curr Rev Pain 3: 226–236PubMedCrossRefGoogle Scholar
  553. 553.
    Gruenwald J, Brendler T, Jaenicke C (1998) PDR for herbal medicine, Vol 1. Medical Economics Company, Oradell/ N.Y.Google Scholar
  554. 554.
    Wood M (1986) Plasma drug binding: implications for anesthesiologists. Anesth Analg 65: 786–804PubMedGoogle Scholar
  555. 555.
    Duthie DJR, Nimmo WS (1987) Adverse effects of opioid analgesics drugs. Br J Anaesth 59: 61–77PubMedCrossRefGoogle Scholar
  556. 556.
    Maurer PM, Bartkowski RR (1993) Drug interactions of clinical significance with opioid analgesics. Druf Safety 8: 30–48CrossRefGoogle Scholar
  557. 557.
    Wilcox GL, Carlson GH, Joachim A, Jurna I (1987) Mutual potentiation of antinociceptive effects of morphine and Clonidine on motor and sensory responses in rat spinal cord. Brain Res 405: 84–93PubMedCrossRefGoogle Scholar
  558. 558.
    Becker CE, Briggs AH, Fleckenstein L, Greenberg BL, Hausten PD, Hussar DA (1974) A quick guide to common drug interaction. In: Bigelow J (ed) Patient care. Miller and Fink, Philadelphia: pp 1–32Google Scholar
  559. 559.
    Hoffmann P (1987) Kombination von Benzodiazepinen und Opioiden. In: Schulte am Esch J, Benzer H (Hrsg) Anal-gosedierung bei Intensivpatienten. Springer, Berlin Heidelberg New York Tokio, pp 50–61 ( Reihe: Anaesthesio-logie und Intensivmedizin, Bd 200 )Google Scholar
  560. 560.
    Kapp W (1981) Pharmakolgische und toxikologische Aspekte zu Benzodiazepinen. Anästh Intensivther Notfallmed 16: 125–127PubMedCrossRefGoogle Scholar
  561. 561.
    Kamp HD (1988) Langzeitsedierung mit Benzodiazepinen. In: Schulte am Esch J, Benzer H (Hrsg) Analgosedierung des Intensivpatienten. Springer, Berlin Heidelberg New York Tokio, pp 35–49 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 200 )Google Scholar
  562. 562.
    Borchard U (1981) Tranquillanzien aus pharmakologischer Sicht. Medica 9: 638–643Google Scholar
  563. 563.
    De Castro J, Parmentier P (1975) Antimorphinques et anesthésie analgésique séquentielle. Ill: Pharmacodynamic des principaux antidotes de la morphine. Academia S.A., BruxellesGoogle Scholar
  564. 564.
    Blum R, Zsigmond EK, Winnie AP (1982) Potentiation of opioid analgesia by Hr and H2-antagonists. Life Sci 31: 1229–1232CrossRefGoogle Scholar
  565. 565.
    Freye E (1992) Die perioperative Behandlung des Arzneimittelabhängigen. Anästh Intensivmed 3: 59–67Google Scholar
  566. 566.
    Rawal N (1996) Klinischer Einsatz der rückenmarknahen Opioidanalgesie, Teil 1. Schmerz 10: 176–189PubMedCrossRefGoogle Scholar
  567. 567.
    Börner U, Müller H, Stoyanov M, Hempelmann G (1980) Epidurale Opiatanalgesie–Gewebe und Liquorverträg-lichkeit der Opiate. Anästhesist 29: 570–571Google Scholar
  568. 568.
    Bürkle H, Dunbar S, van Aken H (1996) Remifentanil: a novel, short-acting, |u-opioid. Anesth Analg 83: 646–651PubMedGoogle Scholar
  569. 569.
    Rawal N, Tandon B (1985) Epidural and intrathecal morphine in intensive care units. Intensive Care Med 11: 129–135PubMedCrossRefGoogle Scholar
  570. 570.
    Stevens CW, Lacey CB, Miller KE, Eide RP, Seybold VS (1991) Biochemical characterization and regional quantification of in, 5 and k opioid binding sites in rat spinal cord. Brain Res 550: 77–85PubMedCrossRefGoogle Scholar
  571. 571.
    De Castro J, Lecron L (1981) Peridurale Opiatanalgesie. Verschiedene Opiate–Komplikationen und Nebenwirkungen. In: Zenz M (Hrsg) Peridurale Opiatanalgesie. G. Fischer, Stuttgart New York, pp 103–109Google Scholar
  572. 572.
    Moore RA, Bullingham RES, McQuay HJ, Hand CW, Aspel JB, Allen MC (1982) Dural permeability to narcotics: in vitro determination and application to extradural administration. Br J Anaesth 54: 1117–1127PubMedCrossRefGoogle Scholar
  573. 573.
    Leicht CH, Rosen MA, Dailey PA et al. (1986) Evaluation and comparison of epidural sufentanil citrate and morphine sulfate for analgesia after cesarean section. Anesthesiology 65: A 365Google Scholar
  574. 574.
    Camporesi EM, Nielsen CH, Bromage PR (1983) Ventilatory C02 sensitivity after intra venous and epidural morphine in volunteers. Anesth Analg 62: 633PubMedCrossRefGoogle Scholar
  575. 575.
    Bromage PR, Camporesi EM, Durant PAC, Nielsen CH (1982) Rostral spread of epidural morphine. Anesthesiology 56: 431–436PubMedCrossRefGoogle Scholar
  576. 576.
    Johnson A, Bengtsson M, Söderlind K, Löfström JB (1992) Influence of intrathecal morphine and naloxone intervention on postoperative ventilatory regulation in elderly patients. Acta Anaesthesiol Scand 36 /5: 436–444PubMedCrossRefGoogle Scholar
  577. 577.
    McCaughey W, Graham IL (1982) The respiratory depression of epidural morphine: time course and effect of posture. Anaesthesia 37: 990–994PubMedCrossRefGoogle Scholar
  578. 578.
    Glynn CI, Mather LE, Cousins ME (1979) Spinal narcotics and respiratory depression. Lancet II: 356Google Scholar
  579. 579.
    Cohen SE, Tan S, White PF (1988) Sufentanil analgesia following cesarean section: epidural vs. intravenous administration. Anesthesiology 68: 129–134PubMedCrossRefGoogle Scholar
  580. 580.
    Chalmer PC, Lang CM, Greenhouse BB (1988) The use of nalbuphine in association with epidural narcotics. Anes-thesiol Rev 15 /2: 21–27Google Scholar
  581. 581.
    Bromage PR, Camporesi EM, Durant PAC (1982) Nonrespiratory side effects of epidural morphine. Anesth Analg 61: 490PubMedGoogle Scholar
  582. 582.
    Rawal N, Möllefors K, Axelsson K (1981) Naloxone reversal of urinary retention after epidural morphine. Lancet II: 1411Google Scholar
  583. 583.
    Cousins MJ, Mather LE (1984) Intrathecal and epidural administration of opioids. Anesthesiology 61: 276–310PubMedCrossRefGoogle Scholar
  584. 584.
    Rawal N, Wattwil M (1982) Respiratory depression after epidural morphine - an experimental and clinical study. Anesth Analg 63: 8Google Scholar
  585. 585.
    Eisenach JC (1992) Epidural and spinal narcotics. In: Barash PG (ed) ASA Refresher courses in anesthesiology, vol 20. Lippincott, Philadelphia, pp 1–4Google Scholar
  586. 586.
    Bailey DR, Smith BE (1980) Continuous epidural infusion of fentanyl for postoperative analgesia. Anesthesiology 42: 538CrossRefGoogle Scholar
  587. 587.
    Davies GK, Tolhurst-Cleaver CL, James TL (1980) Respiratory depression after intrathecal opiates. Anaesthesia 35: 1080PubMedCrossRefGoogle Scholar
  588. 588.
    Gjessing J, Tomlin PJ (1981) Postoperative pain control with intrathecal morphine. Anaesthesia 36: 268PubMedCrossRefGoogle Scholar
  589. 589.
    Rutter DV, Skewes DG, Morgan M (1981) Extradural opioids for postoperative analgesia. A double blind comparison of pethidine, fentanyl and morphine. Br J Anaesth 53: 915Google Scholar
  590. 590.
    Kitahata LM, Collins JG (1981) Spinal action of narcotic analgesics. Anesthesiology 54: 153PubMedCrossRefGoogle Scholar
  591. 591.
    Gourlay GK, Murphy TM, Plummer JL, Kowalski SR, Cherry DA, Cousins MJ (1989) Pharmacokinetics of fentanyl in lumbar and cervical CSF following lumbar epidural and intravenous administration. Pain 38: 253–259PubMedCrossRefGoogle Scholar
  592. 592.
    Weightman WM (1991) Respiratory arrest during epidural infusion of bupivacaine and fentanyl. Anaesth Int Care 19: 282–284Google Scholar
  593. 593.
    Vertommen JD, Vandermeulen E, van Aken H et al. (1991) The effects of the addition of sufentanil to 0.125% bupivacaine on the quality of analgesia during labor and on the incidence of instrumental deliveries. Anesthesiology 74: 809–814PubMedCrossRefGoogle Scholar
  594. 594.
    Justins DM, Knott C, Luthmann J, Reynolds P (1982) A controlled trial of extradural fentanyl in labour. Br J Anaesth 54: 409–414PubMedCrossRefGoogle Scholar
  595. 595.
    Chesnut DH, Owen CL, Bates JN, Ostman LG, Choi WW, Geiger MW (1988) Continuous infusion epidural analgesia during labor: a randomized double-blind comparison of 0.0625% bupivacaine/0.002% fentanyl vs. 0.125% bupivacaine. Anesthesiology 68: 754–758CrossRefGoogle Scholar
  596. 596.
    Fischer RL, Lubenow TR, Liceaga A, McCarthy RJ, Ivanko-vich AD (1988) Comparison of continuous epidural fenta-nyl-bupivacaine and morphine-bupivacaine in management of postoperative pain. Anesth Analg 67: 559–563PubMedCrossRefGoogle Scholar
  597. 597.
    Waldvogel HH, Fasano M (1983) Extradural administration of lofentanyl for balanced postoperative pain. Anästhesist 32: 256–257Google Scholar
  598. 598.
    Durant PAC, Yaksh TL (1986) Epidural injections of bupivacaine, morphine, fentanyl, lofentanil, and DADL in chronically implanted rats: a pharmacologic and pathologic study. Anesthesiology 64: 43–53PubMedCrossRefGoogle Scholar
  599. 599.
    Meert TF, Lu HR, van Craenndonck H, Janssen PAJ (1988) Comparison between epidural fentanyl, sufentanil, carfen-tanil, lofentanil and alfentanil in rats: analgesia and other in vivo effects. Eur J Anaesth 5: 313–321Google Scholar
  600. 600.
    Vertomme JD, Lemmers E, van Aken H (1994) Comparison of the addition of three different doses of sufentanil to 0.125% bupivacaine given epidurally during lanbor. Anaesthesia 49: 678–681CrossRefGoogle Scholar
  601. 601.
    Vandermeulen EP, van Aken H, Vertommen JD (1995) Labor pain relief using bupi vacaine and sufentanil: patient controlled epidural analgesia vs. intermittent injections. Gynecol Reprod Biol 59: 35–38CrossRefGoogle Scholar
  602. 601a.
    Browner G, Mertes N, Buerkle MAF, van Aken H (2000) Acute pain management: analysis implications and consequences after prospective experience with 6349 surgical patients. Eur J Anaesthesiol 17: 566Google Scholar
  603. 602.
    Camann WR, Denney RA, Holby ED, Datta S (1992) A comparison of intrathecal, epidural, and intravenous sufentanil for labor analgesia. Anesthesiology 77: 884–892PubMedCrossRefGoogle Scholar
  604. 603.
    McQuay HJ, Sullivan AS, Smallmann K, Dikenson AH. Intrathecal opioids, potency, and lipophilicity. Pain 1989 36: 111–115PubMedCrossRefGoogle Scholar
  605. 604.
    Hansdottir V, Hedner T, Woestenborghs R, Nordberg G (1991) The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. Anesthesiology 74: 264–269PubMedCrossRefGoogle Scholar
  606. 605.
    D’Angelo R, Anderson MT, Philipp J, Eisenach JC (1994) Intrathecal sufentanil compared to epidural bupivacaine for labor analgesia. Anesthesiology 80: 1209–1215PubMedCrossRefGoogle Scholar
  607. 606.
    Jones RDM, Jones JG (1980) Intrathecal morphine: naloxone reverses respiratory depression but not analgesia. Br Med J 281: 645–646PubMedCrossRefGoogle Scholar
  608. 607.
    Meignier M, Canansia MF, Lejus C, Souron R (1993) Continuous intrathecal opioids and bupivcaine for the mange-ment of intractable cancer pain in children. Anesth Analg 76: S259CrossRefGoogle Scholar
  609. 608.
    Brown DV, McCarthy RJ. Epidural and spinal opioids. Curr Opinion Anaesth 1995 8: 337–341CrossRefGoogle Scholar
  610. 609.
    Cousins MJ (1988) The spinal route of analgesia. Acta Anaesth Belg 39: 71–82PubMedGoogle Scholar
  611. 610.
    Mok MS, Lippmann M, Wang JJ, Chan K, H, Lee TY (1981) Efficacy of epidural nalbuphine in postoperative pain control. Anesthesiology 61: A187Google Scholar
  612. 611.
    Kalia PK, Madan S, Saksena R, Batra RK, Gode GR (1983) Epidural pentazocine for postoperative pain relief. Anesth Analg 62: 949PubMedCrossRefGoogle Scholar
  613. 612.
    Mok MS, Tsai K, Chan KH, Lee TY, Lippman M (1984) Analgesic effect of intrathecal stadol, nubain, meperidine, morphine and fentanyl, a comparative study. VIII. World Congress of Anaesthesiologists. Manila/Philippines, A213Google Scholar
  614. 613.
    Malinovsky JM, Cozian A, Lepage JY, Mussini JM, Pinaud M, Souron R (1991) Ketamine and midazolam neurotoxicity in the rabbit. Anesthesiology 75: 91–97PubMedCrossRefGoogle Scholar
  615. 614.
    Ossipov MH, Suarez LJ, Spaulding TC (1989) Antinociceptive interactions beween alpha2-adrenergic and opiate agonists at the spinal level of rodents. Anesth Analg 68: 194–200PubMedCrossRefGoogle Scholar
  616. 615.
    Carabine UA, Milligan KR, Moor J (1992) Extradural cloni-dine and bupivacaine for postoperative analgesia. 68: 132–135Google Scholar
  617. 616.
    Eisenach JC, Lysak SZ, Viscomi CM (1989) Epidural cloni-dine analgesia following sugery. Phase I. Anesthesiology 71: 640–646Google Scholar
  618. 617.
    Eisenach JC, Rauck RL, Buzzanell C, Lysak SZ (1989) Epidural clonidine analgesia for intractable cancer pain. Phase I. Anesthesiology 71: 647–652Google Scholar
  619. 618.
    Zenz M, Piepenbrock S, Tryba M (1985) Epidural opiates: Long-term experiences in cancer pain. Klin Wochenschr 63: 225–229Google Scholar
  620. 619.
    Herz A (1996) Peripheral opioid analgesia–facts and mechanisms. Progr. Brain Res 110: 95–104CrossRefGoogle Scholar
  621. 620.
    Paton WD (1957) The action of morphine and related substances on the actylcholine output of coaxially stimulated guinea pig ileum. Br J Pharmacol 11: 119Google Scholar
  622. 621.
    Stein C (1993) Peripheral mechanism of opioid analgesia. Anesth Analg 76: 182–191PubMedCrossRefGoogle Scholar
  623. 622.
    Stein C (1993) Periphere Opiatrezeptoren und ihre Bedeutung für die postoperative Schmerztherapie. Schmerz 7: 4–7PubMedCrossRefGoogle Scholar
  624. 623.
    Picard PR, Tramèr MR, McQuay HJ, Moore RA (1997) Analgesie efficacy of peripheral opioids (all except intraarticular): A qualitative systemic review of randomized controlled trials. Pain 72: 309–318Google Scholar
  625. 624.
    Sefrin P (1986) Auswirkungen des Schmerzes als pathogenetischer Faktor in der Notfallmedizin am Beispiel des Polytraumatisierten. In: Sefrin P (Hrsg) Schmerz in der Notfallmedizin. Zuckschwerdt, München, pp 11–20 ( Reihe: Klinische und experimentelle Notfallmedizin, Bd 5 )Google Scholar
  626. 625.
    Jaättela A, Alha A, Avkainen V et al (1975) Plasma catecholamines in severely injured patients: a prospective study on 45 patients with multiple injuries. Br J Surg 62: 177PubMedCrossRefGoogle Scholar
  627. 626.
    Dick W (1978) Schmerzbehandlung im Notfall und der Notsituation. Notfallmed 4: 52Google Scholar
  628. 627.
    Busse C (1987) Notfalltherapie mit Betäubungsmitteln und Analgetika. Notfallmedizin 13: 426–439Google Scholar
  629. 628.
    Sefrin P, Blumenberg D (1988) Präklinische Analgesie bei internistischen Notfall patienten. Notfallmedizin 32: 636–641Google Scholar
  630. 629.
    Pfenninger E (1992) Möglichkeiten der Schmerzbehandlung am Unfallort. Klinikmagazin 3: 20–23Google Scholar
  631. 630.
    Seferin W (1982) Indikationen zur Beatmung und Narkose im Rettungsdienst. In: Schildberg FW, de Pay AW (Hrsg) Atemstörungen im Rettungsdienst. Interdisziplinäre Aspekte. Perimed, Erlangen, pp 153–158Google Scholar
  632. 631.
    Jones J, Hoggart B, Withey J, Donaghue K, Ellis B (1979) What the patients say: A study of reactions to intensive care. Intensive Care Med 5: 89–92Google Scholar
  633. 632.
    Dennhardt R (1986) Fentanyl/Droperidol zur Analgesie und Sedierung bei beatmeten Intensivpatienten. Anästh Akt 11: 1–5Google Scholar
  634. 633.
    Hecht U, Lehmkuhl P, Pichlmayr I (1989) Sedierung zur postoperativen Beatmung: Midazolam vs. Propofol-Erste Ergebnisse. In: Link J, Eyrich K (Hrsg) Analgesie und Sedierung in der Intensivmedizion. Springer, Berlin Heidelberg New York Tokio, pp 99–104 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 212 )Google Scholar
  635. 634.
    Adams HA, Biscoping J, Thiel A, Hempelmann G (1989) Analgosedierung beatmungspflichtiger Intensivpatienten mit einer Ketamin-Midazolam-Kombination. In: Link J, Eyrich K (Hrsg) Analgesie und Sedierung in der Intensivmedizion. Sprin ger, Berlin Heidelberg New York Tokio, pp 105–112 ( Reihe: Anaesthesiologie und Intensiv medi-zin, Bd 212 )Google Scholar
  636. 635.
    Lenhart FP, Frey L, Wilm V, Taeger K (1989) Sedierung langzeitbeatmeter Patienten mit Methohexital und Opio- ¡den. In: Link J, Eyrich K (Hrsg) Analgesie und Sedierung in der Intensivmedizin. Springer, Berlin,Heidelberg, New York, pp 74–84 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 212 )Google Scholar
  637. 636.
    Brandl M, Braun J, Knoll GR, Schütz W (1989) Langzeit-sedierung neurochirurgischer Patienten mit Methohexital. In: Link J, Eyrich K (Hrsg) Analgesie und Sedierung in der Intensivmedizin. Springer, Berlin Heidelberg New York Tokio, pp 64–73 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 212 )Google Scholar
  638. 637.
    Hoffmann P (1987) Möglichkeiten individueller Analgose-dierung in der Intensivmedizin. In: Henschel WF (Hrsg) Anästhesiologie–Klinisches Fach auf drei Säulen. Zuck-schwerdt, München, pp 351–356Google Scholar
  639. 638.
    Kochs E, Bischoff P, Rust U, Schulte am Esch J (1988) Beeinflussung des Hypophysen-Nebennierenrinden-Systems durch Langzeitanalgosedierung. In: Schulte am Esch J, Benzer H (Hrsg) Analgosedierung des Intensivpatienten. Springer, Berlin Heidelberg New York Tokio, pp 62–68 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 200 )Google Scholar
  640. 639.
    Kurth M (1983) Anästhesie und Analgosedierung mit Keta-min bei Patienten einer Intensivstation. Anästh Intensiv-med 24: 270–272Google Scholar
  641. 640.
    Adams HA, Biscoping J, Russ W, Bachmann B, Ratthey K, Hempelmann G (1988) Untersuchungen zur sedativ-anal-getischen Medikation beatmungspflichtiger Patienten. Anästhesist 37: 2658–2676Google Scholar
  642. 641.
    Cohen AT (1987) Experience with alfentanil infusion as an intensive care sedative analgesie. Eur J Anaesthesiol 1: 63–66Google Scholar
  643. 642.
    Farina ML, Levati A, Tognoni GA (1981) A multicentre study of ICU drug utilization. Intensive Care Med 7: 125–131PubMedCrossRefGoogle Scholar
  644. 643.
    Gast PH, Fischer A, Sear JW (1981) Intensive care sedation now. Lancet II: 863–864Google Scholar
  645. 644.
    Kochs E, Schulte am Esch J (1987) Hormone des Hypophy-sen-Nebennierenrindensystems bei Patienten unter Lang-zeitsedierung mit Etomidat und Fentanyl. Anästhesist 33: 402–407Google Scholar
  646. 645.
    Sear JW, Fischer A, Summerfield RJ (1987) Is alfentanil by infusion useful for sedation in the ICU? Eur J Anaesth Supp 1: 55–61Google Scholar
  647. 646.
    Sinclair ME, Sear JW, Summerfield RJ, Fisher A (1988) Alfentanil infusions on the intensive therapy unit. Intensive Care Med 14: 55–59PubMedCrossRefGoogle Scholar
  648. 647.
    Uray E, Kosa CS (1969) Wirkung der bei Neuroleptanal-gesie verwendeten Medikamente auf die Druckwerte der Gallenwege. Anästhesist 18: 74–77Google Scholar
  649. 648.
    Kroesen G, Bodner E, Russe W, Troyer E (1978) Beeinflussung der intraoperativen Cholangiometrie durch Anästhesiemethoden. Anästhesist 27: 21–24Google Scholar
  650. 649.
    Nickel B, Schmickaly R, Kursawe HK et al. (1986) Beitrag zur Therapie der Delirium tremens. Z Klin Med 41: 1643–1646Google Scholar
  651. 650.
    Ohlendorf H, Jong Md, Steenhoek A, Janknegt R (1988) Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther 43: 263–269CrossRefGoogle Scholar
  652. 651.
    Striebel HW, Papadopoulos G, Heinemeyer G, Link J (1989) Langzeitanalgosedierung mit Flunitrazepam, Fentanyl und Dehydrobenzperidol bei schwerstkranken Intensivpatienten: Pharmakokinetik-Pharmakodynamik. In: Link J, Eyrich K (Hrsg) Analgesie und Sedierung in der Intensivmedizin. Springer, Berlin Heidelberg New York Tokio, pp 135–148 ( Reihe: Anaesthesiologie und Intensivmedizin, Bd 212 )Google Scholar
  653. 652.
    Bergmann H (1978) Rohypnol. Pharmakologische Grundlagen - Klinische Anwendung. In: Ahnefeld FW, Bergmann H, Burri H (Hrsg) Klinische Anästhesiologie und Intensivtherapie, Bd. 17. Springer, Berlin Heidelberg New York Tokio, S 130Google Scholar
  654. 653.
    Alazia M, Levron JC (1987) Etude pharmacocinetique d’une perfusion intraveineuse prolongée de fentanyl en réanimation. Ann Fr Anesth Réanim 6: 465–466PubMedCrossRefGoogle Scholar
  655. 654.
    Ramsey MAE, Savage TM, Simpson BNRJ, Goodwin R (1974) Controlled sedation with alphaloxone-alphadone. Br Med J II: 656–659Google Scholar
  656. 655.
    Weiss M, Schneider M, Wernet P (1994) Einfluß von Hyp-notika und Sedativa auf die Immunabwehr. Jahrbuch der Anästhesiologie und Intensivmedizin. Biermann, München, pp 27–37Google Scholar
  657. 656.
    Moudgil GC, Singal DP, Gordon J, Forrest JB (1984) Fentanyl, sufenanil and alfentanil do not inhibit cell-mediated immune response. Anesthesiology 61/3: A 355Google Scholar
  658. 657.
    Kalenda Z, Scheijgrond JW (1976) Anaesthesia with sufen-tanil-analgesia in carotid and vertebral arteriography. A comparison with fentanyl. Anästhesist 25: 380–383Google Scholar
  659. 658.
    Cheour S (1988) Comparison of sufentanil-N20 and fenta-nyl-N20 in patients undergoing general surgery. A blind study. Anesthesiology 69: A213CrossRefGoogle Scholar
  660. 659.
    Wappler F, Scholz J, Prause A, Möllenberg O, Bause H, Schulte am Esch J (1998) Stufenkonzept zur Analgosedierung in der Intensivmedizin mit Sufentanil. Anästhesiol Intensivmed Notfallmed Schmerzther 33: 18–26CrossRefGoogle Scholar
  661. 660.
    Kessler P (1997) Industrieforum: Sufentanil in der klinischen Anwendung–Wo liegen die Vorteile? Anästhesiol Intensivmed 12: 647–652Google Scholar
  662. 661.
    Schwieger IA, Hall Rl, Hug CCH (1991) Less than additive antinociceptive interaction between midazolam and fentanyl in enflurane-anesthetized dogs. Anesthesiology 74: 1060–1066PubMedCrossRefGoogle Scholar
  663. 662.
    Palaoglu O, Ayhan IH (1986) The possible role of benzodiazepine receptors in morphine analgesia. Pharmacol Biochem Behav 25: 215–217PubMedCrossRefGoogle Scholar
  664. 663.
    Tonner PH, Scholz J (1996) Clinical perspectives of alpha-2 adrenoreceptor agonists. Curr Opinion Anaesth 9: 471–480Google Scholar
  665. 664.
    Aantaa R, Kallio A, Virtanen R (1993) Dexmedetomidine, a novel alpha2-adrenergic agonist. A review of its pharmacodynamic profile. Drugs Future 18: 49–56Google Scholar
  666. 665.
    Bredas P, Grounds M, Roedler G, Torres KM (1998) Optimizing analgesia in the intensive care unit. In: Maze M, Morrison P (eds) Redefining sedation. Royal Society of Medicine Press, London, pp 51–61Google Scholar
  667. 666.
    Talke P, Richardson CA, Scheinin M, Fischer DM (1997) Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg 85: 1136–1142PubMedGoogle Scholar
  668. 667.
    Shafer A, White P, Schüttler J, Rosenthal MH (1983) Use of fentanyl infusion in the intensive care unit: Tolerance to its anesthetic effects? Anesthesiology 59: 245–248PubMedGoogle Scholar
  669. 668.
    Gear RW, Miaskowski C, Heller PH, Paul SM, Gordon NC, Levine JD (1997) Benzodiazepine mediated antagonism of opioid analgesia. Pain 71: 25–29PubMedCrossRefGoogle Scholar
  670. 669.
    Daghero AM, Bradley EL, Kissin I (1987) Midazolam antagonizes the analgesic effect of morphine in rats. Anesth Analg 66: 944–947PubMedCrossRefGoogle Scholar
  671. 670.
    Rosland JH, Hole K (1990) Benzodiazepine-induced antagonism of opioid antinociception may be abolished by spinalization or blockade of the benzodiazepine receptor. Pharmacol Biochem Behav 37: 505–509PubMedCrossRefGoogle Scholar
  672. 671.
    Rady JJ, Fujimoto JM (1993) Dynorphin A(1–17) mediates midazolam antagonism of morphine antinociception in mice. Pharmacol Biochem Behav 46: 331–339PubMedCrossRefGoogle Scholar
  673. 672.
    Hofbauer R, Tesinsky P, Hammerschmidt V et al. (1999) No reduction in the sufentanil requirement of elderly patients undergoing ventilatory support in the medical intensive care unit. Eur J Anaesthesiol 16: 702–707PubMedGoogle Scholar
  674. 673.
    Boulard G, Maurette P, Pouguet P et al (1983) Syndrome abstinence après arrêt de la sedation par fentanyl en neuro-reanimation. Ann Fr Anesth Réanim 2: 100–101PubMedCrossRefGoogle Scholar
  675. 674.
    Freye E (1987) Opiate und ihre Antagonisten–Bedeutung der Rezeptorspezifität für die klinische Wirkung. Analgesie und Sedierung in der Intensivmedizin. Infomed Institut für Medizinische Kommunikation, München, pp 19–21Google Scholar
  676. 675.
    Gal TJ, DiFazio CA (1986) Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology 64: 175–180PubMedCrossRefGoogle Scholar
  677. 676.
    Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28: 784–791PubMedCrossRefGoogle Scholar
  678. 677.
    Martin WR (1979) History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol 7: 732CrossRefGoogle Scholar
  679. 678.
    Moore LR, Bikhazi GB, Tuttle RR, Weidler DJ (1990) Antagonism of fentanyl-induced respiratory depression with nalmefene. Meth Find Expt Clin Pharmacol 12 /1: 29–35Google Scholar
  680. 679.
    Nagrajan R, Jeyashree S, Shanmugam M, Subramanian VB, Tuttle RR, Caldwell RW (1992) Reversal effects of morphine by nalmefene. J Clin Res Drug Dev 7: 25–29Google Scholar
  681. 680.
    Flacke JW, Flacke WE, Williams GD (1977) Acute pulmonary edema following naloxone reversal of high dose morphine anesthesia. Anesthesiology 47: 376–378PubMedCrossRefGoogle Scholar
  682. 681.
    Smith TC (1979) Comparison of naloxone and naltrexone in man. Anesthesiology 51: S 573CrossRefGoogle Scholar
  683. 682.
    Goldfrank L, Flamenbaum N, Weismann RS (1981) General management of the poisened overdosed patient. Part 1. Patients in coma with altered mental status. Hosp Physician 17: 24–62Google Scholar
  684. 683.
    Volans GN, Henry JA (1983) Naloxon in der Notfallmedizin. Therapiewoche 33: 2095–2105Google Scholar
  685. 684.
    Freye E, Härtung E, Schenk GK (1983) Effects of the three narcotic antagonists (naltrexone, diprenorphine, S-20682) on blood pressure, heart rate and electrical cortical activity. Pharmacology 26: 110–116PubMedCrossRefGoogle Scholar
  686. 685.
    Volavka J, James B, Reker D, Mallya A, Cho D, Pevnik J (1979) EEG and other effects of naltrexone and heroin in man. Pharmakopsychiat 12: 79–85CrossRefGoogle Scholar
  687. 686.
    Verebey K, Volavka J, Mule SJ, Resnik RB (1976) Naltrexone: Disposition, meta bolism and effects after acute and chronic dosing. Clin Pharmacol Ther 20: 315–328Google Scholar
  688. 687.
    Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T (1987) Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13/1, 2: 1–17CrossRefGoogle Scholar
  689. 688.
    Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880PubMedCrossRefGoogle Scholar
  690. 689.
    ’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49: 881–887CrossRefGoogle Scholar
  691. 690.
    Greenstein RA, Evans BD, McLellan AT, O’Brien C (1983) Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend 12: 173–180PubMedCrossRefGoogle Scholar
  692. 691.
    Sagy M, Shavit G, Oron Y, Vidnre BA, Gitter S, Same Y (1987) Nonopiate effects of naloxone on cardiac muscle contractility. J Cardiovasc Phramacol 9: 682–685CrossRefGoogle Scholar
  693. 692.
    Sanky R (1985) Naloxone abolishes self injuring in a mentally retarded child. Ann Neurol 17: 520CrossRefGoogle Scholar
  694. 693.
    EgarterC (1987) Plasma-Beta-Endorphinspiegel und Nalo-xontest bei Hyperlaktin ämie. Gynäk Rdsch 27: 38–46Google Scholar
  695. 694.
    Faden AI, Jacobs TP, Holaday JW (1981) Opiate antagonist improves neurologic recovery after spinal injury. Science 211: 493PubMedCrossRefGoogle Scholar
  696. 695.
    Stokes BT (1984) Improvement in injury-induced hypocalcemia by high dose naloxone intervention. Brain Res 290: 187PubMedCrossRefGoogle Scholar
  697. 696.
    Barsan WG, Olinger CP, Adams HP et al. (1989) Use of high dose naloxone in acute stroke: Possible side-effects. Crit Care Med 17: 762–767PubMedCrossRefGoogle Scholar
  698. 697.
    Katz J, Kavanagh BP, Sandler AN et al. (1992) Preemptive analgesia-clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 77: 439–446PubMedCrossRefGoogle Scholar
  699. 698.
    Wall PD (1988) The prevention of postoperative pain. Pain 33: 289–290PubMedCrossRefGoogle Scholar
  700. 699.
    Kehlet H (1989) The stress response to surgery: release mechanisms and the modifying effect of pain relief. Acta Chir Scand 550 (Suppl): 22–28Google Scholar
  701. 700.
    Kehlet H (1989) Surgical stress: the role of pain and analgesia. Br J Anaesth 63: 189–195PubMedCrossRefGoogle Scholar
  702. 701.
    Scott NB, Kehlet H (1988) Regional anaesthesia and surgical mobidity. Br J Surg 75: 299–304PubMedGoogle Scholar
  703. 702.
    Woolf CJ (1983) Evidence for a central component of post-injury hypersensitivity. Nature 306: 686–688PubMedCrossRefGoogle Scholar
  704. 703.
    Coderre TJ, Melzack R (1987) Cutaneous hyperalgesia: contribution of the peripheral and central nervous system to the increase in pain sensitivity after injury. Brain Res 404: 95–106PubMedCrossRefGoogle Scholar
  705. 704.
    Cook AJ, Woolf CJ, Wall PD, McMahon SB (1987) Dynamic receptive field plasticity in the rat spinal cord dorsal horn following C-primary afferent input. Nature 325: 151–153PubMedCrossRefGoogle Scholar
  706. 705.
    Wall PD (1988) The prevention of postoperative pain. Pain 33: 289–290PubMedCrossRefGoogle Scholar
  707. 706.
    Lombard MC, Besson JM (1989) Attempts to gauge the relative importance of pre-and postoperative effects of morphine on the transmission of noxious messages in the dorsal horn of the rat spinal cord. Pain 37: 335–345PubMedCrossRefGoogle Scholar
  708. 707.
    Katz J, Kavanagh BP, Sandler AN (1992) Preemptive analgesia: clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 77: 439–446PubMedCrossRefGoogle Scholar
  709. 708.
    Davies SN, Lodge D (1987) Evidence for involvement of N-methylaspertate receptors in »wind-up« of class 2 neurones in the dorsal horn of the rat. Brain Res 424: 402–406PubMedCrossRefGoogle Scholar
  710. 709.
    Hong JS, Yang HY, Fratta W, Costa E (1977) Determination of methionine enkephalin in discrete regions of rat brain. Brain Res 134: 383PubMedCrossRefGoogle Scholar
  711. 710.
    Snyder SH, U’Prichard DC, Greenberg DA (1978) Neurotransmitter receptor binding in the brain. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: A generation of progress. Raven, New York, pp 361–370Google Scholar
  712. 71.
    I.Wood PL (1982) Multiple opiate receptors: Support for unique ju, 5 and k sites. Neuropharmacology 21: 487–497CrossRefGoogle Scholar
  713. 712.
    Wood PL (1984) k agonists analgesics: Evidence for |u2 and 5 opioid receptor antagonism. Drug Dev Res 4: 429–435Google Scholar
  714. 713.
    Kaiser C, Pontecorvo MJ, Mewshaw RE (1991) Sigma receptor ligands: function and activity. Neurotransmissions 7 /1: 1–5Google Scholar
  715. 714.
    McKnight AT, Rees DC (1991) Opioid receptors and their ligands. Neurotransmissions 7 /2: 1–6Google Scholar
  716. 715.
    Kosterlitz HW, Paterson SJ (1980) Characterization of opioid receptors in nervous tissue. Proc R Soc Lond 210: 113–122PubMedCrossRefGoogle Scholar
  717. 716.
    Kockott G (1984) Chronisch, vorwiegend psychisch bedingter Schmerz. MMW 126: 667–672Google Scholar
  718. 717.
    Pinsky JJ (1978) Psychodynamics and psychotherapy in the treatment of patients with chronic pain. In: Crue BL (ed) Chronic Pain. Spectrum, New YorkGoogle Scholar
  719. 718.
    Pilowsky J (1981) Current views on the role of psychiatrists in the management of the chronic pain. In: Swerd-low (ed) The therapy of pain. MTI Press, LancasterGoogle Scholar
  720. 719.
    Smith TW, Hughes J, Kosterlitz HW, Sosa RP (1976) Enkephalins: Isolation, distribution and function. Opiates and Endogenous Opioid Peptides. Elsevier, AmsterdamGoogle Scholar
  721. 720.
    Yeadon M, Kitchen I (1990) Multiple opioid receptors mediate the respiratory depressant effect of fentanyl-like drugs in the rat. Gen Pharmac 21: 655–664CrossRefGoogle Scholar
  722. 721.
    Ling GSF, Spiegel K, Lockhart SH, Pasternak GW (1985) Separation of opioid analgesia from respiratory depression: Evidence of different receptor mechanism. J Pharmacol Exp Ther 232: 149–155Google Scholar
  723. 722.
    Pasternak GW, Wood PJ (1986) Minireview: Multiple mu opiate receptors. Life Sci 38: 1889–1898Google Scholar
  724. 723.
    Pasternak GW (1988) Multiple morphine and enkephalin receptors and the relief of pain. JAMA 259: 1362–1367PubMedCrossRefGoogle Scholar
  725. 724.
    Magnan J, Paterson SJ, Tavani A, Kosterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmie-debergs Arch Pharmacol 319: 197–205CrossRefGoogle Scholar
  726. 725.
    Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146: 185–186PubMedCrossRefGoogle Scholar
  727. 726.
    Weissmann DE, Haddox JD (1989) Opioid pseudoaddic-tion-an iatrogenic syndrome. Pain 36: 363–366CrossRefGoogle Scholar
  728. 727.
    Willweber-Strumpf A, Zenz M, Strumpf M (1992) Medikamentenabhängigkeit bei der Therapie chronischer Schmerzen. Z Gesamt Inn Med 47: 312–317Google Scholar
  729. 728.
    Twycross RG, Lack SA (1983) Symptom control in far-advanced cancer. Pain relief. Pittman, LondonGoogle Scholar
  730. 729.
    Borrison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5: 192–230Google Scholar
  731. 730.
    Havemann U, Turski L, Kuschinsky K (1982) Role of opioid receptors in the substantia nigra in morphine-induced muscular rigidity. Life Sci 31: 2319–2322PubMedCrossRefGoogle Scholar
  732. 731.
    Paakkari P, Feuerstein G (1988) Antagonism of dermor-phin-induced catalepsy with naloxone, TRH-analog CG3703 and the benzodiazepine antagonist, Ro 15–1788. Neuropharmacology 27 /10: 1007–1012PubMedCrossRefGoogle Scholar
  733. 732.
    De Vos V (1978) Immobilization of free-ranging wild animals using a new drug. Vet Ree 103: 64–68CrossRefGoogle Scholar
  734. 733.
    Wörz R, Berlin J (1989) Behandlung chronischer Schmerzsyndrome mit Antidepressiva. Schmerz 3: 1–7PubMedCrossRefGoogle Scholar
  735. 734.
    Atkinson RE, Schofield P, Mellor P (1990) Opioids in the treatment of cancer pain. In: Doyle D (ed) London Int Congress and Symposium Series, London, vol 146, pp 81–87Google Scholar
  736. 735.
    Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind V, Slone D (1970) Comprehensive drug surveillance. JAMA 213: 1455–1460PubMedCrossRefGoogle Scholar
  737. 736.
    Babayan EA, Lepakhin VK, Rudenko GM (1980) Opioid analgesics and narcotic antagonists. In: Dukes MNG (ed) Meyers’s side effects of drugs. Exerpta Medica, Amsterdam, pp 105Google Scholar
  738. 737.
    Schultheiss R, Schramm J, Neidhardt J (1992) Dose changes in long-and medium-term intrathecal morphine therapy of cancer pain. Neurosurgery 31 /4: 664–670PubMedCrossRefGoogle Scholar
  739. 738.
    Bruera E, Brenneis C, Michaud M, Chadwick S, MacDonald RN (1987) Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer. Cancer Treat Rep 71 /10: 953–957PubMedGoogle Scholar
  740. 739.
    Schoon W, Erdmann H, Kleeberg UR (1987) Die kontinuierliche subkutane Opi oid infusion in der onkologischen Schmerztherapie. Med Klin 82 /23: 805–811Google Scholar
  741. 740.
    Goecke H, Herbst M (1993) Ambulante kontinuierliche subkutane Opioidanalgesie als PCAO (patient controlled analgesia in outpatients) bei schweren Tumorschmerzen. Schmerz 7: 31–39CrossRefGoogle Scholar
  742. 741.
    Moulin DE, Johnson NG, Murray-Parson N, Geoghegan MF, Goodwin VA, Chester MA (1992) Subcutaneous narcotic infusions for cancer pain: treatment outcome and giudelines for use. Can Med Assoc J 146 /6: 891–897Google Scholar
  743. 742.
    Herbst M, Goecke H (1991) Ambulante subkutane Infusionsanalgesie mit Opioiden. In: Henschel WF (Hrsg) I. Europäisches Analgesieforum–Die Analgesie im Mittelpunkt der Anästhesie. Urban and Schwarzenberg, München Wien Baltimore, pp 178–187Google Scholar
  744. 743.
    Westerling D, Andersson KE (1984) Rectal administration of morphine hydrogel: Absorption and bioavailability in women. Acta Anaesth Scand 28: 540–543Google Scholar
  745. 744.
    Danny WE (1929) Operative relief from pain in lesions of the mouth. Arch Surg 19: 143–148CrossRefGoogle Scholar
  746. 745.
    Sweet WH (1976) Controlled thermocoagulation of trigeminal ganglion and rootlets for differential destruction of pain fibers. Facial pain other than trigeminal neuralgia. Clin Neurosurg 23: 96–102PubMedGoogle Scholar
  747. 746.
    Young RF, Brechner T (1986) Electrical stimulation of the brain for relief of intractable pain due to cancer. Cancer 57: 1266–1272PubMedCrossRefGoogle Scholar
  748. 747.
    Lobato RD, Madrd JL, Fatela LV, Rivas JJ, Reig E, Lamas E (1983) Intraventricular morphine for control of pain in terminal cancer patients. J Neurosurg 59: 627–633PubMedCrossRefGoogle Scholar
  749. 748.
    Obbens EAMT, Hill CS, Leavens ME, Ruthenbeck SS, Otis F (1987) Intraventricular morphine administration for control of chronic cancer pain. Pain 28: 61–68PubMedCrossRefGoogle Scholar
  750. 749.
    Sandouk P, Serrie A, Urtizberra M, Debray M, Got P, Scherrmann JM (1991) Morphine pharmacokinetics and pain assessment after intracerebroventricular administration in patients with terminal cancer. Clin Pharmacol Ther 49: 442–448PubMedCrossRefGoogle Scholar
  751. 750.
    Dennis GC, DeWitty RL (1990) Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 26 /3: 404–407PubMedCrossRefGoogle Scholar
  752. 751.
    Lehmann KA, Einnolf C, Eberlein HJ, Nagel R (1991) Transdermal fentanyl for the treatment of pain after major uro-logical operations. A randmized double-blind comparison with pacebo using intravenous patient-controlled analgesia. Eur J Clin Pharmacol 41 /1: 17–21PubMedCrossRefGoogle Scholar
  753. 752.
    De Castro J, Van de Water A, Wouters L, Xhonneux R, Reneman R, Kay B (1979) Comparative study of cardiovascular, neurological, and metabolic side effects of eight narcotics in dogs. Acta Anaesth Belg 30: 5–99PubMedGoogle Scholar
  754. 753.
    Ghignone M (1987) Effects of clonidine on narcotic requirements and hemodynamic response during induction of fenanyl anesthesia and endotracheal intubation. Anesthesiology 67: 3–10PubMedCrossRefGoogle Scholar
  755. 754.
    Fahmy NR, Sunder N, Scoter NA (1984) A comparison of histamine-releasing properties and hemodynamic effects of morphine and nalbuphine in humans. Anesth Analg 63: 210Google Scholar
  756. 755.
    Hermann DJ, Marton JP, Donn KH et al (1991) Pharmacokinetic comparison of GI87084B, a novel ultra-short acting opioid, and alfentanil. Anesthesiology 75: A 379Google Scholar
  757. 756.
    Herz A, Teschemacher HJ (1971) Activities and site of antinociceptive action of morphine-like analgesics. Adv Drug Res 6: 79–119Google Scholar
  758. 757.
    Ferreira SH, Nakamura M (1979) Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalin and opioid antagonists. Prostaglandins 18: 191–200PubMedCrossRefGoogle Scholar
  759. 758.
    Joris JL, Dubner R, Hargreaves KM (1987) Opioid analgesia at peripheral sites: a target for opioid released during stress and inflammation. Anesth Analg 66: 1277–1281PubMedCrossRefGoogle Scholar
  760. 759.
    Stein C, Comisel K, Haimerl E et al. (1991) Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med 325: 1123–1 126Google Scholar
  761. 760.
    Raja SN, Dickstein RE, Johnson CA (1992) Comparison of postoperative analgesic effects of intraarticular bupiva-caine and morphine following arthroscopic knee surgery. Anesthesiology 77 /6: 1143–1147PubMedCrossRefGoogle Scholar
  762. 761.
    Joshi GP, McCarroll SM, O’Brien TM, Lanane P (1993) Intraarticular analgesia following knee arthroscopy. Anest Analg 76: 333–336Google Scholar
  763. 762.
    Bailey PL, Streisand JB, East KA et al. (1990) Differences in magnitude and duration of opioid induced respiratory depression and analgesia with fentanyl and sufentanil. Anesth Analg 70: 8–15PubMedCrossRefGoogle Scholar
  764. 763.
    Hughes MA, Glass PSA, Jacobs JR (1992) Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 76: 334–341PubMedCrossRefGoogle Scholar
  765. 764.
    Herz A (1981) Opiat-Partialantagonisten. In: Kubicki S, Neuhaus GA (Hrsg) Pentazocin im Spiegel der Erfahrungen. Springer, Berlin Heidelberg New York Tokio, pp 19–21Google Scholar
  766. 765.
    Freye E, Latasch L, Portoghese PS (1992) The delta receptor is envolved in sufentanil-induced respiratory depression. Eur J Anaesthesiol 9: 457–462PubMedGoogle Scholar
  767. 766.
    Eisenach JC (1992) Epidural and spinal narcotics. In: Barash PG (ed) ASA Refresher courses in anesthesiology, vol 20. Lippincott, Philadelphia, pp 1–4Google Scholar
  768. 767.
    Twycross RG (1988) Opioid analgesics in cancer pain: current practice and controversies. Cancer Sur 7: 29–53Google Scholar
  769. 768.
    Cookson RF (1983) Carfentanil and Lofentanil. Clin Anaesthesiol 1: 156–158Google Scholar
  770. 769.
    Janssen PAJ (1984) The development of new synthetic narcotics. In: Estafanous FG (ed) Opioids in anesthesia. Butterworth, Boston, pp 37–44Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Enno Freye
    • 1
  1. 1.Neuss-UedesheimDeutschland

Personalised recommendations